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1.4.  Summary 
mTOR (mammalian target of rapamycin) regulates cell growth and 
metabolism.  mTOR forms two independent complexes, termed mTORC1 
(mTOR complex 1) and mTORC2, both are frequently activated in tumors.  
TSC1 and PTEN are two tumor suppressors and upstream regulators of the 
mTOR pathway. 
To investigate the role of mTOR in liver tumor development, we used 
mice in which Tsc1 and Pten are deleted in the liver (hereafter referred to as, 
L-dKO mice).  L-dKO mice exhibited sustained mTORC1 and mTORC2 
activation, and invariably developed liver tumors.  To identify mechanisms 
governing tumor development, we performed longitudinal unbiased 
quantitative proteomic and phosphoproteomic analyses on livers from L-dKO 
mice and littermate controls.  Most prominently, fatty acid (FA) and lipid 
synthesis pathways were up-regulated in L-dKO mice.  Indeed, L-dKO mice 
displayed enhanced hepatic de novo FA synthesis, hepatosteatosis followed 
by the appearance of tumors.  Longitudinal lipidomic analyses of livers from 
L-dKO mice revealed increased accumulation of sphingolipid (SL) and 
glycerophospholipid  (PL), particularly of cardiolipin (CL).  CL accumulation 
correlated with hyper-tubular mitochondria in hepatocytes and improved 
oxidative phosphorylation (OxPhos).  Inhibition of de novo FA or SL synthesis 
reduced tumor burden.  Furthermore, L-dKO mice preferentially synthesized 
and accumulated the SL glucosylceramide (GlcCer).  To examine whether 
GlcCer are necessary for tumor development, we knocked down GCS 
(Glucosylceramide Synthase), the rate-limiting enzyme of GlcCer synthesis.  
GCS inhibition in hepatocytes reduced tumor burden.  Together these data 
indicates that FA and lipids are required for tumor development. 
Lastly, we investigated whether mTORC1 and/or mTORC2 promoted FA 
and lipid synthesis.  Pharmacological inhibition studies indicated that 
mTORC2 promoted FA synthesis, via SREBP1c.  Indeed, genetic deletion of 
Rictor, an essential component of mTORC2, in L-dKO mice (L-TriKO) 
reduced hepatic FA, CL and SL (GlcCer) accumulation.  Importantly, L-TriKO 
mice also exhibited reduced liver tumor number and size, compared to L-dKO 
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mice.  Thus, mTORC2 promotes FA and lipid accumulation and ultimately 
tumor development. 
Collectively, this thesis provides mechanistic insights for the role of 
mTORC2 in promoting tumor development, via FA and lipid synthesis.  Lipids 
are required for tumor growth, as macromolecules, but also to support 
mitochondrial function to match increased energy demand.  Inhibition of FA or 
lipid synthesis pathways kills cancer cells, thus exposing a cancer-specific 
vulnerability that can be exploited for the rational design of targeted cancer 
drugs. 
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1.5.  Novel findings 
1.  Oncogenic mTORC2 promotes fatty acid and lipid synthesis. 
2.  Cancer cells require fatty acids for growth and proliferation. 
3.  Cancer cells require sphingolipid, particularly glucosylceramide for    
    growth. 
4.  mTORC2, via fatty acid and lipids, increases cancer cell biomass  
    and improves mitochondrial function. 
 
Graphical Abstract 
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2.0.  Introduction 
2.1.  Fatty acids 
2.1.1.  Fatty acid synthesis 
Fatty acid (FA) synthesis is induced by growth factors, through the 
transcription factor SREBP-1c (Sterol Regulatory Element-Binding Protein-1).  
SREBP-1c is produced as inactive precursor, upon cleavage (SREBP-1c 
mature) it translocates to the nucleus (Wang, Sato et al. 1994).  Mature 
SREBP-1c stimulates the expression of genes involved in FA biosynthesis, 
including Acac, Fasn, Scd1 and Elovl6 (Jeon and Osborne 2012) (Diagram 1).  
FA synthesis requires acetyl groups that are derived from the tricarboxylic 
(TCA) cycle, in the form of citrate.  Citrate exits the mitochondrion to the 
cytoplasm via a ‘citrate shuttle’.  ACLY (ATP-Citrate Lyase) converts 
cytoplasmic citrate into acetyl-CoA and oxaloacetate.  Oxaloacetate can be 
converted into pyruvate, generating NADPH that replenishes reducing power 
for lipid synthesis.  ACC (Acetyl-CoA Carboxylase) converts acetyl-CoA to 
malonyl-CoA.  Acetyl and malonyl groups are then coupled to the acyl-carrier 
protein domain of FASN (Fatty Acid Synthase).  FASN by repeated 
condensation steps generates palmitate (basic 16 carbon unit).  Palmitate is 
introduced with a double bond in the Δ9 position by SCD1 (Stearoyl-CoA 
Desaturase 1), thereby generating mono-unsaturated FAs (MUFA).  Other FA 
desaturases (FADS) generate highly polyunsaturated fatty acids (PUFA) 
mainly from dietary essential PUFA (Lee, Lee et al. 2016).  FAs can be 
further elongated by ELOVL (Elongation Of Very Long Chain Fatty Acids), a 
family of seven enzymes (ELOVL1-7) with different chain length and 
saturation affinities (Guillou, Zadravec et al. 2010).  The ER localized 
ELOVL1-7 synthesize long chain fatty acids (VLCFAs), by adding two 
carbons in each cycle.  Once generated, the various FAs have many fates, 
including being stored for energy, incorporated into membrane or signaling. 
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Diagram 1.  De novo fatty acid and lipid synthesis.  For simplification 
selected enzymes are depicted. 
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2.2.  Lipids 
 
2.2.1.  Lipid synthesis: Sphingolipids 
Sphingolipid (SL) is a group of lipids in which FAs are linked via amide bonds 
to a long-chain base (LCB), also called sphingoid (Christie 2013).  SL 
requires the amino acid serine as the backbone to which acyl chains are 
attached  (Diagram 2).  The synthesis of SL begins at the ER, where two 
important precursors: LCB and VLCFA are produced (the latter described 
above).  Generation of LCB is the rate-limiting reaction for de novo SL 
biosynthesis, catalyzed by SPT (Serine Palmitoyltransferase) (Breslow 2013).  
SPT condense serine and palmitoyl-CoA to generate 3-keto-
dihydrosphingosine (also known as 3-keto-sphinganine, 3kSN), which is then 
reduced to yield the LCB dihydrosphingosine (also known as sphinganine, 
SN).  LCB is N-acylated, with fatty acids of different lengths, by CerS 
(Ceramide Synthase, isoforms 1 to 6) to produce dihydroceramide (dhCER).  
CerS1-6 exhibits different FA specificities, hence the structural heterogeneity 
among SL species.  Fatty acids used for sphingolipid synthesis are produced 
by ELOVL (see above).  Ceramides undergo headgroup modifications in the 
Golgi apparatus to yield Sphingomyelin (SM) or glucosylceramide (GlcCer).  
GCS (glucosylceramide synthase) catalyzes the rate-limiting step of GlcCer 
synthesis, adding glucose (obtained from UDP-glucose) to ceramide. 
The reverse reactions of most steps described above delineates the SL 
catabolism (Diagram 1).  SM hydrolysis by membrane bound nSMase 
(neutral-Sphingomyelinase, a.k.a SMPD2 or 3) or lysosomal aSMAse (acid-
SMase, a.k.a SMPD1) yields in ceramide and phosphocholine.  Similarly, 
glycohydrolases such as GBA (glucosylceramidase beta) and GBA2 remove 
head group from GlcCer, thereby counteracting the action of GCS.  
Sphingolipid production is tuned in response to metabolic needs.  For 
example, alterations in cellular serine concentration affect SPT activity, while 
sphingolipid level may reduce that of serine (Cowart and Hannun 2007).  
Another mode of regulation is via the ORMDL (mammalian homologues of 
the yeast ORM) that inhibit SPT activity (Siow, Sunkara et al. 2015, Siow, 
Sunkara et al. 2015). 
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Diagram 2.  Sphingolipid Structure.  Sphingoid Base, N-Acyl group, Headgroup. 
Adapted from LIPID MAPS, www.lipidmaps.org. 
 
 
2.2.2.  Lipid synthesis: Glycerophospholipids 
Glycerophospholipid (PL) contain fatty acids esterified (sn-1 - 2) to a glycerol 
backbone and a head group connected by a phosphate (sn-3) (Diagram 3) 
(Aguilera-Romero, Gehin et al. 2014).  GPAT (glycerol 3-phosphate 
acyltransferase, isoforms GPAT1 to 3) generates lysophosphatidic acid (LPA), 
adding a fatty acid to glycerol 3-phosphate on the sn-1 position (Diagram 1).  
LPA is then converted by AGPAT (Acylglycerol-3-Acyltransferase) to a 
phosphatidic acid (PA).  PA can be used for the synthesis of PL in two 
mechanisms that require nucleotides (described below).  PAP (Phosphatidic 
Acid Phosphatase), also known as lipin (isoforms 1 to 3), converts PA to 
diacylglycerol (DAG).  DAG is covalently connected to a long chain fatty acid 
by DAGT (Diglyceride Acyltransferase 1 or 2), generating triacylglyceride 
(TG) that can be stored in lipid droplets.  Alternatively, DAG is connected 
choline or ethanolamine (from a nucleotide cytidine pyrophosphate carrier, 
CDP-choline or -ethanolamine), thereby generating phosphatidylcholine (PC) 
or phosphatidylethanolamine (PE), respectively (Gibellini and Smith 2010).   
Instead, DAG is connected to CDP yielding the liponucleotide, CDP-DAG 
(Diagram 1).  CDP-DAG generated by CDS (CDP-DAG synthase 1 or 2), is 
required for the synthesis of the glycerophospholipids phosphatidylinositol 
(PI), phosphatidylserine (PS) and cardiolipin (CL, a.k.a. 
diphosphatidylglycerol). 
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Diagram 3.  Glycerophospholipid structure.  PL can be divided into 
different subgroups (defined by the head-group). The head group can consist 
of choline, ethanolamine, inositol, serine or glycerol. Modified from (Burri, 
Hoem et al. 2012). 
 
2.2.3.  Cardiolipin 
CLs are exclusively synthesized in the mitochondria (Schlame and Haldar 
1993, Schlame, Rua et al. 2000).  The rate-liming step in CL biosynthesis is 
catalyzed by PGS1 (Phosphatidylglycerol-phosphate Synthase 1).  PGS1 
condenses the liponucleotide CDP-DAG and glycerol-3-phosphate (releasing 
a CMP), producing a short-lived phosphatidylglycerol-phosphate (PGP).  
PGP is dephosphorylated by the PTEN-like mitochondrial phosphatase 
PTPMT1, generating a phosphatidylglycerol (PG) (Zhang, Guan et al. 2011).  
Cardiolipin synthase (CRLS1) links PG to a CDP-DAG (yet another 
liponucleotide molecule), synthesizing an immature CL.  CL is then 
remodeled into a mature tetralinoleoyl-CL (4 linoleolic acid chains (C18:2)), 
by several enzymes.  The catalytic center of the mitochondrial protein CRLS1 
is exposed to the matrix side of the inner mitochondrial membrane (IMM) 
(Schlame and Haldar 1993, Schlame, Rua et al. 2000).  CL lodged in the IMM, 
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providing stability for the enzyme complexes involved in energy production 
(Houtkooper and Vaz 2008, Duncan, Robinson et al. 2016). Furthermore, 
CLs appears to be important for mitochondrial fusion (Joshi, Thompson et al. 
2012), which is associated with improved mitochondrial function (van der 
Bliek, Shen et al. 2013, Yu-Wai-Man, Carelli et al. 2014).  Thus, FAs are used 
also for CL synthesis, which is required for mitochondria function. 
 
2.3.  The TOR signaling pathway 
2.3.1.  mTORC1 and mTORC2 components 
The evolutionarily conserved serine/threonine kinase Target of Rapamycin 
(TOR) integrates various stimuli to control the metabolic pathways that drive 
cell growth.  TOR forms two structurally and functionally separate protein 
complexes termed TOR Complex 1 (TORC1) and TORC2 (Wullschleger, 
Loewith et al. 2006, Laplante and Sabatini 2012).  Mammalian TORC1 
(mTORC1) contains mTOR, mLST8 (mammalian lethal with sec-13 protein 8), 
and RAPTOR (regulatory associated protein of mammalian target of 
rapamycin).  mTORC2 contains mTOR, mLST8, mSIN1 (mammalian stress-
activated map kinase-interacting protein 1), and RICTOR (rapamycin-
insensitive companion of mTOR) (Diagram 4). 
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Diagram 4.  The mTOR-signaling pathway.  mTOR promotes anabolic and inhibits catabolic 
processes and ultimately leads to cell growth (Yakir Guri 2016).   
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2.3.2.  Upstream of mTORC1 and mTORC2 
mTORC1 is activated by amino acids, cellular energy and growth factors 
(Dibble and Manning 2013, Shimobayashi and Hall 2014).  Growth factors 
and cellular energy stimulate mTORC1 via inhibition of a heterotrimeric 
protein complex consisting of tuberous sclerosis complex 1 (TSC1), TSC2 
and TBC1D7 (TRE2-BUB2-CDC16 domain family member 7) (Inoki, Li et al. 
2002, Kenerson, Aicher et al. 2002, Manning, Tee et al. 2002, Tee, Manning 
et al. 2003, Sancak, Peterson et al. 2008), referred to as the TSC complex.  
mTORC1 is activated by amino acids through the RAG (RAS-related GTP-
binding protein) family of small GTPases (Long, Lin et al. 2005, Kim, 
Goraksha-Hicks et al. 2008).  RAGA or RAGB forms heterodimer with either 
RAGC or RAGD.  Amino acids stimulate the conversion of the RAG 
heterodimers to the active conformation, in which RAGA or RAGB is loaded 
with GTP and RAGC or RAGD is loaded with GDP.  Once activated, RAG 
heterodimer recruits mTORC1 to the surface of the lysosome to bind GTP-
loaded RHEB (RAS homologue enriched in brain), thereby activating 
mTORC1 (Dibble and Cantley 2015). 
Growth factors bind RTK (Receptor Tyrosine Kinases) to activate 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K).  PI3K generates 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) by phosphorylating the 
membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2) 
(Pearce, Komander et al. 2010).  PIP3 recruits PDK1 (Phosphoinositide-
Dependent Kinase 1) and AKT to the plasma membrane, where PDK1 
phosphorylates AKT at Thr308 (Alessi, James et al. 1997).  PTEN 
(Phosphatase and Tensin Homolog Deleted on Chromosome 10) negatively 
regulated the mTOR signaling, by converting PIP3 to PIP2, thereby 
counteracting the activity of PI3K.  AKT inhibits the TSC complex by 
phosphorylating TSC2, of the TSC complex (Menon, Dibble et al. 2014).  The 
TSC complex is a GAP (GTPase-Activating Protein) for RHEB (RAS 
Homologue Enriched in Brain).  High AMP/ATP ratio (low cellular energy 
level) activates AMPK (AMP-Activated Protein Kinase).  AMPK 
phosphorylates TSC2, thereby stimulating the GAP activity of the TSC 
complex towards RHEB, to inhibit mTORC1 (Corradetti, Inoki et al. 2004, 
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Inoki, Ouyang et al. 2006).  AMPK also inhibits mTORC1 via phosphorylation 
of RAPTOR.  When intracellular ATP level are high, AMPK is inactive, 
relieving the mTORC1 inhibition. 
Mechanisms of mTORC2 activation are less defined (Sparks and Guertin 
2010, Shimobayashi and Hall 2014).  Growth factors activate mTORC2 by 
promoting its association with ribosomes, in a PI3K dependent manner (Frias, 
Thoreen et al. 2006, Yang, Inoki et al. 2006, Zinzalla, Stracka et al. 2011).  
Recently, PI3K was suggested to trigger mTORC2 activation via PIP3 
interaction with the PH domain of mSIN1 (Liu, Gan et al. 2015). 
 
2.3.3.  Downstream of mTORC1 and mTORC2 
mTOR signaling promotes anabolic and inhibits catabolic processes.  
mTORC1 controls protein synthesis via S6K (ribosomal protein S6 kinase)  
and 4E-BPs (4E binding proteins).  mTORC1 phosphorylates 4E-BPs,  which 
is then dissociated from eIF4E (eukaryotic translation initiator factor 4E).  
eIF4E in its free form bind eIF4G at the 5’ end of mRNAs, thereby promoting 
cap-dependent translation initiation.  mTORC1 phosphorylates S6K at the 
Thr389 leading to its activation.  Active pS6K phosphorylates and activates 
S6 ribosomal protein on several residues (Ser235, Ser236, Ser240 and 
Ser244) (Ben-Sahra, Howell et al. 2013, Robitaille, Christen et al. 2013).  S6, 
in turn, stimulates the expression of several genes involved in ribosome 
biosynthesis (Chauvin, Koka et al. 2014).  S6K also regulates protein 
biosynthesis via direct phosphorylation of other proteins involved in 
translation or mRNA processing, including eIF4B, eIF2K and PDCD4 
(reviewed in (Shimobayashi and Hall 2014)).  mTORC1-S6K phosphorylates 
and inhibits the autophagy activating Unc-51-like kinase 1 (ULK1) [Reviewed 
in (Mamane, Petroulakis et al. 2006, Ma and Blenis 2009, Kim, Kundu et al. 
2011)].  Thus, mTORC1 regulates protein synthesis on multiple levels and 
inhibits autophagy. 
mTORC2 regulates several cellular processes via the AGC kinase family 
members AKT, protein kinase C α (PKCα), and serum/glucocorticoid-
regulated kinase (SGK) [reviewed in (Cybulski and Hall 2009, Sparks and 
Guertin 2010)].  mTORC2 controls the actin cytoskeleton organization 
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through PKCα, paxilin and the small GTPases RHO and RAC (Jacinto, 
Loewith et al. 2004, Sarbassov, Ali et al. 2004). 
In a positive feedback loop, AKT phosphorylates mSIN1-Thr86 in 
mTORC2 (Yang, Murashige et al. 2015).  In a negative feedback loop, 
mTORC1 via S6K phosphorylates and inhibits the IRS-1 (Insulin Receptor 
Substrate 1), thereby dampening PI3K-AKT signaling (Takano, Usui et al. 
2001, Um, Frigerio et al. 2004).  The macrolide rapamycin acutely inhibits 
mTORC1.  The ATP-site competitive inhibitor, INK128 inhibits both mTORC1 
and mTORC2 (Benjamin, Colombi et al. 2011).  mTOR, often in the context of 
positive and negative feedback loops, is a node for convergence and 
crosstalk of several oncogenic pathways (Diagram 4) (Efeyan and Sabatini 
2010, Chandarlapaty, Sawai et al. 2011, Shimobayashi and Hall 2014, 
Eltschinger and Loewith 2016). 
 
2.3.4.  mTOR promotes fatty acid and nucleotide synthesis 
mTOR promotes FA synthesis (Ricoult and Manning 2013, Albert and Hall 
2015, Caron, Richard et al. 2015).  However, conflicting evidences exist 
regarding the specific contribution of mTORC1 and mTORC2.  As mentioned 
above, FA synthesis is activated by the transcription factor SREBP-1c.  AKT 
transcriptionally regulates SREBP-1c (Porstmann, Griffiths et al. 2005).  In 
retinal pigment cells and mouse derived embryonic fibroblasts, mTORC1 
induced SREBP-1c processing via S6K (S6 kinase) (Porstmann, Santos et al. 
2008, Duvel, Yecies et al. 2010) (Diagram 5).  In rat liver, SREBP-1c 
expression was blocked by rapamycin, but this appeared to be independent 
of S6K (Li, Brown et al. 2010).  In another mechanism, mTORC1 
phosphorylates the phosphatidic-acid phosphatase, lipin-1.  Lipin-1 is an 
inhibitor of SREBP-1, once phosphorylated lipin-1 is excluded from the 
nucleus, thereby allowing SREBP-1 to induce FA synthesis (Peterson, 
Sengupta et al. 2011).  Together, these studies suggest that mTORC1 
promotes de novo lipogenesis via SREBP-1c. 
Several lines of evidences question the role of mTORC1 in promoting 
hepatic de novo lipogenesis.  First, liver-specific Tsc1 knockout mice 
(exhibiting constitutive active mTORC1) do not exhibit increased SREBP-1c 
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expression or de novo lipogenesis.  Moreover, these mice are protected from 
age and diet induced hepatosteatosis (Yecies, Zhang et al. 2011, Cornu, 
Oppliger et al. 2014).  This was suggested being due to mTORC1-S6K 
mediated negative feedback loop, and reduced PI3K-AKT-mTORC2 signaling.  
However, as recently demonstrated, Tsc1 and S6K double knockout mice fed 
high-fat diet displayed increased hepatic TG content, but exhibited 
unchanged mTORC2 signaling (Kenerson, Subramanian et al. 2015).  
Although more experiments are required, the latter study suggests that the 
effect of mTORC1 on hepatic TG content is independent of the negative 
feedback loop.  Furthermore, rapamycin treatment failed to prevent hepatic 
steatosis in liver-specific Pten knockout mice, in which both mTORC1 and 
mTORC2 are ectopically activated (Kenerson, Yeh et al. 2011), also 
suggesting the hepatosteatosis in these mice is independent of mTORC1.  
Lastly, adenovirus-mediated hepatic Raptor knockdown did not alter hepatic 
triglyceride (TG) content in mice; reduction of hepatic TG was observed only 
when mice were fed high fat diet (Peterson, Sengupta et al. 2011).  More 
recently, liver-specific Raptor knockout mice were generated (driven by an 
albumin promoter), and exhibited no change in hepatic TG content even 
when are fed with high-fat diet (Umemura, Park et al. 2014).  In contrast, 
liver-specific Rictor knockout mice (abrogated mTORC2 activity) exhibited 
reduced SREBP-1c expression and hepatic TG content (Hagiwara, Cornu et 
al. 2012, Liu, Gan et al. 2013), indicating that mTORC2 promotes hepatic de 
novo synthesis, and probably not mTORC1. 
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Diagram 5.  mTOR promotes lipid synthesis via SREBP.  (Shimobayashi and Hall 
2014). 
 
FA provides essential building block for lipid synthesis.  Except, lipid 
synthesis requires other constituents, such as nucleotides, and reducing 
power in the form of NADPH.  Such constituents can be obtained from the 
pentose phosphate pathway (PPP) and nucleotide synthesis pathways.  In 
that regard, mTOR provides another mode of regulation for lipid synthesis. 
mTORC1 activates PPP, thereby stimulating synthesis of precursors for 
nucleotide biosynthesis and generates NADPH (Duvel, Yecies et al. 2010).  
Furthermore, mTORC1 phosphorylates (Ser1859) and activates CAD 
(Carbamoyl Phosphate Synthetase 2, Aspartate Transcarbamylase, and 
Dihydroorotase) (Ben-Sahra, Howell et al. 2013, Robitaille, Christen et al. 
2013).  CAD is a tri-functional enzyme that catalyzes the first three steps in 
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the de novo pyrimidine biosynthesis.  Pyrimidines (uracil, thymine and 
cytosine) are high-energy molecules that drive molecular reactions.  As 
described above, the rate-limiting steps of the lipids GlcCer and CL requires 
uridine and cytidine, respectively.  mTORC1 promotes transcriptionally the 
expression of enzymes contributing to purine synthesis, also in cancer cell 
lines (Ben-Sahra, Hoxhaj et al. 2016).  mTORC2 does not drive nucleotide 
biosynthesis, but might do so by stimulating the expression of the PPP via 
activation of SREBP-1c.  Thus, mTOR signaling, FA, lipid and nucleotide 
synthesis are functionally related. 
 
2.3.5.  mTORC2 is functionally at MAM 
mTORC2 is at the contact sites between mitochondria and endoplasmic 
reticulum (ER), also known as the mitochondria-associated membrane 
(MAM) (Vance 1990, Betz, Stracka et al. 2013).  Tethering of mitochondria to 
the ER is mediated mainly by IP3R-Grp75-VDAC1 complex or the dimer 
MFN1 (Mitofusin 1) and MFN2 (Raturi and Simmen 2013).  MAM is enriched 
in enzymes involved in calcium signaling and lipid metabolism (Dennis and 
Kennedy 1972).  mTORC2 is necessary for efficient calcium transmission 
from the ER to the mitochondria (Bononi, Missiroli et al. 2012, Betz, Stracka 
et al. 2013).  From lipid synthesis standpoint, several enzymes of the PL 
biosynthesis are at MAM, including DGAT 2, PEMT2 
(Phosphatidylethanolamine N-Methyltransferase), ACSL4 (Acyl-CoA 
Synthetase Long-Chain Family Member 4) and PSS1 (Phosphatidylserine 
Synthase 1).  Noteworthy, liver-specific Rictor knockout mice displayed 
reduced MAM formation (Betz, Stracka et al. 2013) and reduced TG 
synthesis (Hagiwara, Cornu et al. 2012).  Thus, mTORC2 is functionally at 
MAM, an important site for lipid synthesis (Betz and Hall 2013, Betz, Stracka 
et al. 2013), and may account for its role in promoting lipid synthesis. 
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2.4.  mTOR signaling in cancer 
mTORC1 and mTORC2 are frequently activated in cancer (Dazert and Hall 
2011, Yecies and Manning 2011, Zoncu, Efeyan et al. 2011, Laplante and 
Sabatini 2012, Bhat, Sonenberg et al. 2013, Cornu, Albert et al. 2013, Albert 
and Hall 2015, Mischel 2015).  mTORC1 is aberrantly activated in human 
tumor syndromes, such as neurofibromatosis (NF1/2 mutations), Cowden’s 
(PTEN mutation), Peutz-Jeghers and tuberous sclerosis complex (TSC1/2 
mutations) and Lymphangioleiomyomatosis (LAM) (TSC2 mutations) (Inoki 
and Guan 2009, Mester and Charis 2015, Ngeow and Eng 2016).  Mice with 
liver-specific deletion of Tsc1 (Menon, Yecies et al. 2012) or Pten (Horie, 
Suzuki et al. 2004, Stiles, Wang et al. 2004) develop liver cancer at about 
one year of age.  mTORC1 promotes tumor development by increasing 
protein synthesis via phosphorylation of 4E-BP1 and S6K1 (Dowling, 
Topisirovic et al. 2010).  Possibly by stimulating selective translation of 
oncogenes (Hsieh, Liu et al. 2012) or by promoting translational elongation 
(Faller, Jackson et al. 2015) and c-Myc expression (Csibi, Lee et al. 2014) 
(Reviewed in (Hsieh and Ruggero 2010, Pelletier, Graff et al. 2015)) 
mTORC2 is also required for tumor development (Guertin, Stevens et al. 
2009), but much less is known about the mechanism(s).  In glioblastoma 
multiforme with EGFRvIII (Epidermal Growth Factor Receptor, variant III) 
amplification, RICTOR acetylation and enhanced mTORC2 activity was 
observed (Masui, Tanaka et al. 2013, Masui, Cavenee et al. 2014, Masui, 
Tanaka et al. 2015, Mischel 2015).  mTORC2 appeared to promote cancer 
drugs resistance, via the nuclear factor NF-kappa-B (NF-κB) (Tanaka, Babic 
et al. 2011), or via transcriptional regulation of the oncoprotein c-MYC (Masui, 
Tanaka et al. 2013). 
 
2.4.1.  mTOR in metabolic reprogramming of cancer cells 
Cancer cells sustain growth and proliferation by activating distinct metabolic 
features (Schulze and Harris 2012).  As such, cancer cells adapt to changes 
in their microenvironment (oxygen, pH, glucose or nutrient concentrations), a 
process referred to as metabolic ‘rewiring’ or ‘reprogramming’ (DeBerardinis, 
Lum et al. 2008, Pavlova and Thompson 2016).  mTOR is both central 
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controller of cellular metabolism and a convergence node for several 
oncogenic pathways (Mendoza, Er et al. 2011, Eltschinger and Loewith 2016).  
Therefore, metabolic flexibility in tumors might be a direct or indirect effect of 
cells displaying oncogenic mutation that activate mTOR. 
In the presence of oxygen, non-cancerous cells transport cytosolic 
pyruvate into the mitochondria.  Mitochondrial pyruvate is then 
decarboxylated to form acetyl-CoA (coenzyme A) by the pyruvate 
dehydrogenase (PDH) complex (PDHC).  Acetyl-CoA is required for oxidative 
phosphorylation and lipid biosynthesis (Pietrocola, Galluzzi et al. 2015).  In 
contrast, rapidly proliferating cells convert excess of pyruvate to lactate 
(aerobic glycolysis a.k.a ‘Warburg effect’) (Warburg 1956).  As a result, 
rapidly proliferating cells exhibit compensatory increase in glucose uptake 
and lactate production.  PDH kinase 1 (PDHK1) phosphorylates and 
inactivates mitochondrial PDH and consequently the PDHC, allowing 
glycolytic metabolites (carbon sources) be diverted to fuel anabolic processes 
including, de novo serine, pentose and lipid synthesis (Kim, Tchernyshyov et 
al. 2006, Papandreou, Cairns et al. 2006, Hitosugi, Fan et al. 2011, Olson, 
Schell et al. 2016). 
Recent studies suggest a central role for mTOR signaling in controlling 
cancer cell metabolic reprogramming (Pavlova and Thompson 2016).  For 
example, cancer cells exposed to the glycolysis inhibitor (2-DG) exhibited 
sustained mTORC1 activity and enhanced mitochondrial and growth 
(Pusapati, Daemen et al. 2016).  mTORC1 activation appeared to be via 
glutaminolysis (Duran and Hall 2012, Duran, Oppliger et al. 2012), these data 
suggests that mTORC1 can be activated by the tumor-metabolic environment.  
Indeed, glutamine-activated mTORC1 was recently shown to underlie 
resistance to angiogenesis inhibitors (Allen, Mieville et al. 2016, Jimenez-
Valerio, Martinez-Lozano et al. 2016, Pisarsky, Bill et al. 2016).  mTORC2 
addicted cancer cell lines also exhibited increased mitochondrial activity, 
probably in addition to aerobic glycolysis (Colombi, Molle et al. 2011).  
Collectively, the above indicates that mTOR promotes cancer, via activation 
of distinct metabolic pathways to increase cell mass and proliferation.  
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2.4.2.  Lipids and cancer 
Cancer cells display elevated FA synthesis, while non-cancer cells rely on 
exogenous sources (bloodstream) (Medes, Thomas et al. 1953, Spirtes, 
Medes et al. 1953).  Enzymes involved in FA synthesis ACC, FASN, SCD1 
and ELOVL6 are frequently upregulate, across cancer types (Medes, Thomas 
et al. 1953, Spirtes, Medes et al. 1953, Kuhajda, Jenner et al. 1994, Li, Ding 
et al. 1994, Menendez and Lupu 2007, Flavin, Peluso et al. 2010, Park, Lee 
et al. 2010, Santos and Schulze 2012, Baenke, Peck et al. 2013, Bae, Oh et 
al. 2016, Feng, Chen et al. 2016, Peck and Schulze 2016).  However, to date, 
the regulation and function of lipid accumulation remains elusive. 
As described above, under physiological conditions mTOR promotes FA 
synthesis.  Whether mTOR can promote cancer via an increase of FAs is 
poorly defined.  High-grade Pten mutated prostate tumors displayed 
cholesteryl-ester accumulation in lipid droplets, suggesting a role for PI3K-
AKT in altering lipid droplet composition in tumors (Yue, Li et al. 2014).  
Breast cancer cell lines expressing oncogenic PI3K or K-RAS exhibit 
enhanced de novo FA synthesis, which appeared to be mediated by 
mTORC1 (Ricoult, Yecies et al. 2015).  While others suggested that 
mTORC2 may promote tumor progression via the expression of FASN (Li, 
Pilo et al. 2016).  Thus, further studies are required to elucidate the 
oncogenic role of mTORC1 and/or mTORC2 and FA synthesis.  
FAs are the building blocks of lipids (described above).  However, to our 
knowledge, no study examined the role of mTOR signaling in mediating lipid 
synthesis in tumors.  Owing to technological advances, tumor lipid phenotype 
can be determined, in particular abundance, composition and spatial 
distribution (Beloribi-Djefaflia, Vasseur et al. 2016).  Indeed, breast tumors, 
compared to adjacent non-tumor tissue, displayed a unique ‘phosphilipid 
signature’ (Hilvo, Denkert et al. 2011, Guenther, Muirhead et al. 2015).  
Similarly, invasive breast cancer cells displayed poly-unsaturated fatty acids 
incorporated to PI, as compared to in situ carcinoma (non-invasive).  Thus, 
changes in lipid composition/accumulation are associated with cancer 
aggressiveness (Kawashima, Iwamoto et al. 2013).  Unlike breast cancers, 
renal cell and hepatocellular carcinoma exhibited increased 
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phosphatidylglycerol (PG), a CL precursor.  Altered CL composition was 
reported in mitochondria from different brain tumors (astrocytoma, 
ependymoblastoma and microglioma) (Kiebish, Han et al. 2008).  Suggesting 
a cancer-specific alteration in CL composition.  This data suggests that 
various oncogenic pathway induce changes in lipid abundance and 
composition. 
In pancreatic tumors, enhanced cholesterol uptake appeared to activate 
ERK1/2 pathway (Guillaumond, Bidaut et al. 2015).  Thus, not only oncogenic 
signaling alters lipid composition, but also lipids can activate oncogenic 
pathways, thereby amplifying oncogenic signaling. 
Sphingolipids may promote or inhibit tumors.  Ceramide is a potent ‘tumor 
suppressor lipid’, by inducing apoptosis or autophagy.  Autophagy, however, 
can also yield cancer cell survival.  Overall, cancer cell preferentially 
upregulate ceramide degrading enzymes, thereby escaping apoptosis.  One 
such pathway, to promptly eliminate ceramide, is by ceramide glycosylation.  
Ceramide glycosylation is chiefly catalyzed by glucosylceramide synthase 
(GCS), thereby providing an escape route from ceramide-induced apoptosis 
(Liu, Han et al. 2000, Ogretmen and Hannun 2004, Gupta, Patwardhan et al. 
2010, Gupta, Bhinge et al. 2012, Kartal Yandim, Apohan et al. 2013, Liu, Hill 
et al. 2013, Tyler, Johansson et al. 2015). 
 
2.4.3.  NAFLD and liver cancer 
Liver cancer is the fifth most common cancer worldwide and has poor 
prognosis accounting for about 600.000 deaths annually (Llovet, Zucman-
Rossi et al. 2016).  One risk factor for liver cancer is Non-Alcoholic Fatty Liver 
Disease (NAFLD).  NAFLD is the most prevalent liver disease western 
countries (Bellentani, Scaglioni et al. 2010, Baffy 2013, Fazel, Koenig et al. 
2016, Lonardo, Byrne et al. 2016).  NAFLD is characterized by excessive 
accumulation of FAs in hepatocytes, in about ~30% of patients it is due to 
enhanced de novo fatty acid (FA) synthesis.  Tissue damage in NAFLD can 
be further amplified by inflammation (Wolf, Adili et al. 2014, Ma, Kesarwala et 
al. 2016), a condition referred to as non-alcoholic steatohepatitis (NASH) 
(Park, Lee et al. 2010, Scherer and Dufour 2016).  NAFLD or NASH patients 
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may progress to HCC (even without developing liver cirrhosis) (Mittal, Sada 
et al. 2015). 
Studies using high fat diet (HFD) or modified diet regimens (methionine-
choline deficient) with or without parallel DEN (diethylnitrosamine) 
administration are frequently used as a model for NAFLD and NASH (Park, 
Lee et al. 2010, Wolf, Adili et al. 2014, Ma, Kesarwala et al. 2016).  Although 
useful, in majority of cases mice are fed HFD, therefore examining the effect 
of hyper-nutrition, and not that of de novo FA and lipid synthesis.  In this 
thesis we separate the contribution of hyper-nutrition from that of de novo 
fatty acid and lipid synthesis. 
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3.0.  Aims of thesis 
1.  Full biochemical and histological characterization of L-dKO mice 
(liver cancer mouse model). 
2.  Examination of the effects of hepatic mTOR-activation on the 
whole-body. 
3.  Global analysis (proteome and phosphoproteome) of mTOR-driven 
tumors – to elucidate early oncogenic mechanisms downstream of 
mTOR signaling. 
 
The above led to the discovery that L-dKO mice exhibit increased fatty acid 
and lipid synthesis and develop hepatosteatosis, prior to the appearance of 
liver tumors.  I therefore set out to examine the following, 
 
1.  What lipid species are deregulated in L-dKO mice and are possibly 
controlled by mTOR signaling (lipidomics was performed in 
collaboration with the lab of Howard Riezman). 
2.  Is there a causal relationship between fatty acids and/or lipid 
accumulation and tumor development? 
3.  What is/are the function(s) of fatty acids and lipids in tumors. 
4.  To elucidate whether the above is mTORC1 or mTORC2 
dependent. 
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Inspiration 
Various oncogenic mutations lead to sustained mTOR activation (see 
appendix).  The question that inspired me was (and still is), what are the 
mechanisms downstream of mTOR required for tumor development. 
Importantly, the basic (and key) trait of this thesis is the use of longitudinal 
studies.  This approach allowed us to identify that fatty acid and lipid 
synthesis occur prior to tumor development and persist within tumors.  In this 
thesis we provide evidence that mTOR-driven tumors require fatty acids and 
lipids for development.  Moreover, we demonstrate that the above is primarily 
controlled by mTORC2.  We hope that these studies provide a better 
understanding for the oncogenic role of mTOR and lipids, and will stimulate 
the usage of FA or lipid pathways inhibitors as (co-) therapy for cancer. 
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4.  Results (manuscript) 
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Summary 
 
Dysregulated mammalian TOR (mTOR) promotes cancer, but underlying 
mechanisms are poorly understood.  We describe an mTOR-driven mouse 
model that displays hepatosteatosis progressing to hepatocellular carcinoma 
(HCC).  Longitudinal proteomic, lipidomic and metabolomic analyses 
revealed that hepatic mTORC2 promotes de novo fatty acid and lipid 
synthesis, and thereby tumorigenesis.  In particular, mTORC2 stimulated 
sphingolipid (glucoceramide) and glycerophospholipid (cardiolipin) synthesis.  
Inhibition of fatty acid or sphingolipid synthesis prevented tumor development.  
Increased levels of cardiolipin were associated with tubular mitochondria and 
enhanced oxidative phosphorylation.  Thus, mTORC2 promotes cancer via 
formation of lipids essential for growth and energy production.  Collectively, 
these findings illustrate a role for mTORC2 in lipid-mediated oncogenesis that 
could be exploited for targeted cancer therapies. 
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Introduction 
 
Cancer is a disorder characterized by increased metabolic activity leading to 
enhanced cell growth and proliferation.  Thus, cancer cells exhibit metabolic 
features that are distinct from non-cancerous cells (DeBerardinis, Lum et al. 
2008, Schulze and Harris 2012, Pavlova and Thompson 2016).  One such 
feature is elevated fatty acid (FA) synthesis, while non-cancerous cells rely 
on exogenous sources (Medes, Thomas et al. 1953, Spirtes, Medes et al. 
1953).  Various enzymes that mediate fatty acid and lipid synthesis are 
transcriptionally up-regulated in tumors (Kuhajda, Jenner et al. 1994, Li, Ding 
et al. 1994, Menendez and Lupu 2007, Flavin, Peluso et al. 2010, Park, Lee 
et al. 2010, Schulze and Downward 2011, Santos and Schulze 2012, Baenke, 
Peck et al. 2013, Bae, Oh et al. 2016, Feng, Chen et al. 2016, Peck and 
Schulze 2016).  Although clinical trials for lipogenesis inhibitors are ongoing 
(Beloribi-Djefaflia, Vasseur et al. 2016), the regulation and function of lipids in 
tumors remain elusive. 
Liver cancer is the fifth most common cancer worldwide and has poor 
prognosis, accounting for about 600,000 deaths annually (Llovet, Zucman-
Rossi et al. 2016).  One risk factor for liver cancer is Non-Alcoholic Fatty Liver 
Disease (NAFLD).  NAFLD is characterized by excessive accumulation of 
triglycerides (TG) in hepatocytes (also known as hepatosteatosis), due in part 
to enhanced hepatic de novo FA synthesis (Lambert, Ramos-Roman et al. 
2014, Sanders and Griffin 2016).  NAFLD may progresses to Non-Alcoholic 
Steatohepatitis (NASH) and ultimately HCC (Postic and Girard 2008). 
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FA synthesis is induced by growth factors, through the transcription factor 
SREBP1c (Sterol Regulatory Element-Binding Protein-1c).  Upon growth 
factor stimulation, precursor SREBP1c is proteolytically processed to yield 
mature SREBP1c, which is translocated into the nucleus to activate 
expression of the FA biosynthesis genes Acc, Fasn, Scd1 and Elovl6 (Horton, 
Goldstein et al. 2002).  
FAs are assembled from acetyl groups derived mainly from citrate.  
Citrate produced by the TCA cycle in mitochondria is shuttled to the 
cytoplasm and converted, by ACLY (ATP-Citrate Lyase), to acetyl-CoA and 
oxaloacetate.  Oxaloacetate is converted to pyruvate, generating NADPH that 
provides reducing power for lipid synthesis.  Acetyl-CoA is converted to 
malonyl-CoA by ACC (Acetyl-CoA Carboxylase).  FASN (Fatty Acid 
Synthase) then condenses malonyl-CoA and several molecules of acetyl-CoA 
to produce palmitate (16 carbon unit).  SCD1 (Stearoyl-CoA Desaturase 1) 
desaturates palmitate thereby generating mono-unsaturated FA.  Other FA 
desaturases (FADS) generate highly polyunsaturated fatty acids (PUFA) (Lee, 
Lee et al. 2016).  FAs can be stored in the form of triacylglycerol (TG).  
Alternatively, FAs are utilized for the synthesis of sphingolipids (SLs) and 
glycerophospholipids (PLs) that are ultimately used as signaling molecules or 
membrane building blocks.  PLs, including mitochondria-specific cardiolipin, 
are the major lipid constituent of cellular membranes. 
The evolutionarily conserved Ser/Thr kinase Target of Rapamycin (TOR) 
controls metabolic pathways that mediate cell growth.  TOR forms two 
structurally and functionally distinct protein complexes termed TOR Complex 
1 (TORC1) and TORC2 (Loewith, Jacinto et al. 2002, Wullschleger, Loewith 
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et al. 2006).  Mammalian TORC1 (mTORC1) is activated by nutrients, growth 
factors and cellular energy (Laplante and Sabatini 2012, Dibble and Manning 
2013, Shimobayashi and Hall 2016).  Growth factors stimulate mTORC1 via 
PI3K-PDK1-AKT mediated inhibition of the negative regulator and tumor 
suppressor TSC, consisting of TSC1 and TSC2 (Inoki, Li et al. 2002, 
Kenerson, Aicher et al. 2002, Kwiatkowski, Zhang et al. 2002, Manning, Tee 
et al. 2002, Tee, Fingar et al. 2002, Dibble, Elis et al. 2012).  The tumor 
suppressor PTEN (Phosphatase and tensin homolog deleted on chromosome 
10) negatively regulates both mTORC1 and mTORC2 signaling.  mTORC1 
directly or indirectly phosphorylates S6K (Ribosomal Protein S6 Kinase), 
ribosomal protein S6, CAD (Carbamoyl Phosphate Synthetase 2, Aspartate 
Transcarbamylase, and Dihydroorotase), and ULK (Unc-51 Like Autophagy 
Activating Kinase 1) among others.  Growth factors activate mTORC2 via 
PI3K dependent association of mTORC2 with the ribosome (Zinzalla, Stracka 
et al. 2011).  mTORC2 phosphorylates several members of the AGC kinase 
family, including AKT, to control various cellular process (Dibble and Manning 
2013, Shimobayashi and Hall 2016).  mTORC2 physiologically controls 
hepatic fatty acid synthesis via AKT and SREBP1c (Hagiwara, Cornu et al. 
2012). mTORC2 is also tumorigenic (Guertin, Stevens et al. 2009, Masui, 
Tanaka et al. 2013, Masui, Tanaka et al. 2015), but little is known about the 
underling mechanism(s).  Tumors frequently exhibit activated SREBP1c 
(Ricoult, Yecies et al. 2015, Li, Pilo et al. 2016).  Rapamycin acutely inhibits 
only mTORC1 whereas INK128 inhibits both mTORC1 and mTORC2 
(Benjamin, Colombi et al. 2011, Hsieh, Liu et al. 2012). 
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Here we demonstrate that, in liver-specific Tsc1 Pten double knockout (L-
dKO) mice, mTORC2 promotes elevated hepatic fatty acid and lipid 
(sphingolipid, cardiolipin) synthesis, and thereby hepatosteatosis and 
hepatocellular carcinoma (HCC).  Enhanced cardiolipin synthesis leads to 
increased mitochondrial activity and energy production.  Thus, mTORC2 is 
oncogenic via lipogenesis. 
 
Results 
 
Liver specific activation of mTOR signaling promotes FA synthesis, 
hepatosteatosis, and HCC. 
To study the role of mTOR signaling in cancer, we generated mice lacking 
both Tsc1 and Pten specifically in the liver (termed L-dKO mice).  The L-dKO 
(Tsc1loxP/loxP; PtenloxP/loxP; Alb-CRE) mice exhibited reduced expression of 
TSC1 and PTEN in the liver, and concomitant activation of mTORC1 and 
mTORC2 signaling, as compared to age-matched littermate control mice 
(Tsc1loxP/loxP; PtenloxP/loxP) (Figure 1A).  The L-dKO mice displayed 
disproportionately increased liver weight (hepatomegaly), beginning at 4 
weeks of age, which was independent of feeding behavior (Figure S1A-C).  L-
dKO mice also exhibited increased serum levels of the liver damage markers 
ALT, AST and LDH (Figure S1D), and elevated hepatic expression of the 
cancer-associated genes Afp and Aldh (Figure S1E).  L-dKO mice invariably 
presented liver cancer, detected microscopically, at about 12 weeks of age 
and died at 20 weeks of age, at which time the liver was replete with tumors 
(Figure S1A).  Histological analysis confirmed liver cancer, hepatocellular 
	   39 
carcinoma (HCC) and rarely (~10%) cholangiocarcinoma (CC) (Figure 1B 
H&E panel and Figure S1F).  A fibrotic rim, indicative of NASH, demarcated 
the tumors (Figure S1G SR and PAS panel).  To confirm that tumors 
correlate with increased proliferation, BrdU incorporation was assessed.  L-
dKO and control mice at 16 weeks of age (at which time tumor and non-tumor 
regions can be readily discriminated) were injected IP with BrdU (n=3).  As 
expected, hepatocyte proliferation was higher in tumors (Figure S1H), 
compared to non-tumor regions and control liver.  Collectively, and consistent 
with previous studies (Kenerson, Aicher et al. 2002, Kenerson, Yeh et al. 
2013), the above indicates that dysregulated hepatic mTOR causes liver 
cancer. 
To identify early, mTOR-dependent molecular events that promote liver 
cancer development, we performed longitudinal, unbiased quantitative 
proteomics and phosphoproteomics on liver samples from 4, 8 and 12 week-
old L-dKO mice and age-matched littermates.  Pathway enrichment analysis 
of proteins and phosphorylation events that were consistently and 
significantly (>2 fold) up- or down-regulated at all three ages (Figure S2A, B) 
revealed enrichment of FA and lipid synthesis pathways (Figures 1C and S2C, 
D).  Importantly, FA and lipid synthesis pathways were up-regulated 
specifically in livers developing HCC, i.e., livers from L-dKO mice.  
Immunoblot analysis confirmed increased expression of FA synthesis 
enzymes ACC, FASN and SCD1 in liver lysates from L-dKO mice, compared 
to control mice (Figure 1A).  Immunoblotting also showed increased levels of 
mature SREBP1c (Figure 1A) while quantitative PCR analysis revealed 
increased expression of the Acc1, Fasn, and Scd1 genes (Figure S2E), 
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indicating that the increase in expression of FA synthesis enzymes was at the 
transcriptional level.  Additionally, phosphoproteomics revealed increased 
ACLY-Ser455 phosphorylation (pACLY-Ser455) in livers of L-dKO mice, 
possibly leading to ACLY activation (Das, Morvan et al. 2015).  pACLY-
Ser455 was also validated by immunoblotting (Figure 1A).  Expression of 
CD36, a long-chain fatty acid transporter that contributes to hepatosteatosis 
(Zhou, Febbraio et al. 2008, Steneberg, Sykaras et al. 2015), was also 
increased in liver of L-dKO mice (Figures 1A, S2F), suggesting enhanced FA 
uptake in addition to synthesis.  Up-regulation of lipid biosynthesis pathways 
was also confirmed, as described further below.  Isolated liver tumors from 20 
week-old L-dKO mice (12 tumors, from 4 mice) also displayed increased 
expression of FA and lipid synthesis pathways, as determined by proteomic 
and RNA sequencing (RNAseq) analyses and confirmed by immunoblotting 
(Figure 1C and Table S1).  We note that in biochemical experiments in which 
we use liver samples from 20 week-old mice, the samples are excised tumors, 
whereas samples from younger mice (4, 8 and 12 weeks) are whole liver.  
We next investigated FA accumulation (hepatosteatosis) and its 
correlation with tumor development.  Macroscopically, livers from L-dKO mice 
appeared fatty starting at 8 weeks of age (Figure S1A).  Lipid droplet specific 
Oil-red-O (ORO) staining confirmed hepatosteatosis (Figure 1D and Figure 
S1F).  H&E staining revealed enlarged hepatocytes, likely due to a 
combination of lipid droplet accumulation and mTOR driven cell growth 
(Figures S1F and S2G, H).  Consistent with enhanced lipid droplet 
accumulation, hepatic TG levels were increased in 4, 8, 12 and 20 week-old 
L-dKO mice, compared to control mice (Figure 1D).  Hepatic TG 
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accumulation was more pronounced in ad-libitum fed mice compared to mice 
starved overnight (Figure S2I).  We note that all subsequent experiments 
were performed with ad-libitum fed mice.  The above indicates that FA 
accumulation precedes HCC in L-dKO mice, as observed clinically. 
To investigate the effect of activated hepatic mTOR signaling on whole-
body metabolism, we performed indirect calorimetry on L-dKO and control 
mice at 12 and 20 weeks of age.  The respiratory exchange ratio (RER) was 
lower in L-dKO, compared to control mice, despite little-to-no difference in 
feeding behavior or physical activity, suggesting that L-dKO mice are more 
reliant on FA oxidation for energy production (Figure S3A-C).  L-dKO mice 
were unaltered in total fat or lean mass compared to controls, as determined 
by longitudinal whole-body fat composition analyses (EchoMRI) (Figure S3D).  
Since L-dKO mice displayed hepatosteatosis and hepatomegaly but did not 
exhibit an overall increase in fat or lean mass, we investigated whether L-
dKO mice exhibit cancer cachexia (wasting syndrome) that may offset the 
increased liver mass.  Cachexia is characterized by substantial tissue loss, in 
particular skeletal muscle and adipose tissue (Argiles, Busquets et al. 2014).  
Indeed, L-dKO mice exhibited reduced skeletal muscle and adipose tissue 
mass compared to control mice (Figure S3E, F).  Hepatic expression of 
genes involved in lipid secretion (Apob, Mttp) or degradation (Atgl, Acox1, 
Mcad, Cpt1), as well as LDL and HDL levels were not changed (Figure S3G, 
H).  Thus, L-dKO mice exhibit whole body cachexia-like effects. 
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FA synthesis is required for tumor development. 
To determine whether FA synthesis is required for tumor development, 6 to 8 
week-old L-dKO (n=4) and littermate control (n=5) mice were treated with the 
FASN inhibitor orlistat (120 mg/kg/bw) or drug vehicle alone (Kridel, Axelrod 
et al. 2004, Seguin, Carvalho et al. 2012, Sounni, Cimino et al. 2014) daily for 
12 weeks.  Orlistat treated L-dKO mice displayed significantly fewer hepatic 
lipid droplets and liver tumors, compared to L-dKO mice treated with drug 
vehicle alone (Figures 2A and S4A, B).  Orlistat treatment did not reduce total 
liver or body weight (Figure S4C).  Furthermore, Orlistat treatment had no 
effect on the phosphorylation status of AKT-Ser473 and S6-Ser235/6 (Figure 
S4D), indicating that drug action was not via inhibition of mTOR.  Thus, FA 
synthesis required for tumor development. 
To determine if FA synthesis in the liver is required for tumor 
development, we used adenovirus associated virus (AAV) to knockdown 
FASN specifically in hepatocytes.  Importantly, to achieve hepatocyte specific 
knockdown, we used an AAV with high liver tropism and expressing shFASN 
from the albumin promoter (AAV-DJ-Albumin-shFASN-RFP, hereafter 
referred to as AAV-shFASN) (Figure S4E).  AAV-shFASN or the control virus 
AAV-shScrmbl (AAV-DJ-Albumin-shScrmbl-RFP) was injected into the tail 
vein of 6 to 8 week-old L-dKO (n=4) and control (n=3) mice.  FASN 
knockdown was confirmed by immunoblotting, qPCR and 
immunofluorescence (Figure S4F-I).  Tumor burden was assessed in mice 
sacrificed at 20 weeks of age.  L-dKO mice infected with AAV-shFASN 
exhibited significantly reduced hepatocyte proliferation and tumor burden, 
compared to L-dKO mice treated with AAV-shScrmbl (Figure 2B).  
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Importantly, AAV-shFASN did not have a detrimental effect in wild-type mice, 
indicating that in contrast to transformed hepatocytes, normal hepatocytes 
are not dependent on FASN expression.  Control mice lacking tumors 
presumably obtain sufficient FAs from the diet.  Collectively, these data 
indicate that hepatic FA synthesis is required for tumor development in 
mTOR driven HCC. 
 
mTOR promotes do novo sphingolipid synthesis: Glucosylceramide. 
The transcriptomic and proteomic analyses described above suggested that 
mTOR promotes lipid synthesis in addition to FA synthesis.  In particular, 
enzymes mediating sphingolipid (SL) and glycerophospholipid (PL) synthesis 
were up-regulated in the liver of young L-dKO mice (4, 8, or 12 weeks) and in 
tumors of 20 week-old L-dKO mice (Figure 1C). 
The rate-limiting reaction in de novo SL biosynthesis is the condensation 
of serine and palmitate catalyzed by SPT (Serine Palmitoyltransferase) to 
generate 3-keto-sphinganine (3kSN) (Aguilera-Romero, Gehin et al. 2014, 
Garcia-Barros, Coant et al. 2014) (Figure 1C).  3kSN is then reduced to yield 
the long chain base (LCB) sphinganine (SN).  LCB is N-acylated, with fatty 
acid chains of different lengths, by CerS (Ceramide Synthase, isoforms 1 to 
6) to produce dihydroceramide (dhCer).  The fatty acids used for sphingolipid 
synthesis are produced by ELOVL (Elongation of Very Long Chain Fatty 
Acids), comprising a family of seven isoforms.  DES (Dihydroceramide 
Desaturase, isoforms 1 and 2) adds a double bond to complete the synthesis 
of ceramide.  Ceramide undergoes head group modifications in the golgi to 
yield sphingomyelin (SM) or glucosylceramide (GlcCer).  GlcCer synthesis is 
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catalyzed by GCS (Glucosylceramide Synthase) that transfers glucose from 
uridine diphosphate (UDP) glucose to ceramide.  Ceramide can also be 
converted to sphingosine (SP) by ceramidases.  SL biosynthetic enzymes, 
including SPT and CerS, are implicated in NAFLD (Pagadala, Kasumov et al. 
2012) and cancer (Ogretmen and Hannun 2004, Levy and Futerman 2010).  
L-dKO mice exhibited increased expression (mRNA and protein) of 
sphingolipid anabolic enzymes, in particular SPT, ELOVL (isoforms 1, 4, 6 
and 7), CerS (isoforms 2, 3, 5 and 6), DES (isoforms 1 and 2), and GCS 
(Figures 1C).  Expression of enzymes that mediate reverse, catabolic steps 
was not altered, with the exception of SMPD (isoforms 1 to 4) and GBA 
(isoforms 1 to 2) that were increased and decreased, respectively (Figure 1C).  
Importantly, increased SMPD and decreased GBA expression suggests that 
GlcCer synthesis is favored in L-dKO mice.  SPK1 (Sphingosine Kinase 1) 
and SPL1 (Sphingosine Lyase 1) that mediate sphingosine 1 phosphate 
(S1P) metabolism downstream of ceramide were also up-regulated (see 
Discussion).  Altered expression of SPT, GCS, SMPD (isoforms 1 and 3), and 
SPK1 was confirmed by immunoblotting or qPCR (Figures 1A, 3A and S5A).  
Immunofluorescence on perfused livers from 8 week-old L-dKO and control 
mice indicated that increased SPT expression was specific to hepatocytes 
(Figure S5B).  These findings suggest that de novo SL synthesis is increased 
in hepatocytes from L-dKO mice, likely leading to GlcCer accumulation. 
To determine whether the above changes in expression lead to changes 
in lipid accumulation, we performed longitudinal unbiased semi-quantitative 
lipidomic analysis on liver samples from 4, 8, 12 and 20 (tumors) week-old L-
dKO mice and age-matched littermates (n=6, per time point).  Lipid 
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enrichment analysis revealed that L-dKO mice exhibit enhanced 
accumulation of dhCer, ceramide, and GlcCer (Figure 4A; Table S2).  As 
suggested by the above transcriptomic and proteomic analyses (Figure 1C), 
the most pronounced accumulation was of GlcCer.  The observed GluCer 
accumulation in livers of L-dKO mice was validated by immunofluorescence 
analysis on frozen liver sections (Figure S5C).  Thus, liver of L-dKO mice 
accumulates sphingolipids, preferentially GlcCer. 
To confirm that de novo SL synthesis, as opposed to SL salvage 
pathways that can also produce elevated levels of GlcCer, was high in L-dKO 
mice we performed metabolomic analysis on liver samples from 4, 8, 12 and 
20 week-old L-dKO mice and control littermates.  Indeed, sphinganine (SN), 
an intermediate of de novo synthesis, was increased in liver samples from L-
dKO mice (Figure 3B).  Moreover, metabolomic analysis indicated that the 
level of the amino acid serine, which is required for the rate-limiting step in de 
novo SL synthesis, was consistently reduced in liver samples from L-dKO 
mice (Figure 3C).  Alanine and glutamine levels were not similarly depleted 
(Figure S5D), suggesting that the reduction in serine is due to consumption 
by de novo SL synthesis.  Thus, consistent with the observed increase in fatty 
acid synthesis, L-dKO mice display increased hepatic de novo SL synthesis. 
 
Sphingolipid (GlcCer) is required for liver tumor development. 
To determine whether the observed increase in de novo SL synthesis is 
required for tumor development, 8 week-old L-dKO (n=5) and littermate 
control (n=5) mice were treated with the SPT inhibitor myriocin.  Myriocin 
(0.03 mg/kg/bw) or drug vehicle alone was IP administered every second day.  
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At 20 weeks of age, mice were euthanized, livers were dissected and liver 
tumors were counted.  Myriocin treatment significantly reduced the number of 
liver tumors in L-dKO mice (Figure 3E).  This effect was further illustrated by 
principle component analysis (Figure S5E).  Myriocin had no effect on the 
phosphorylation status of AKT-Ser473 and S6-Ser235/6, suggesting that the 
drug acted independently of mTOR signaling (Figure S5F).  Liver and body 
weights of L-dKO and control mice treated with myriocin were unchanged 
(Figure S5G).  Lipidomic analysis confirmed the in vivo action of myriocin 
(Figure 3D).  Thus, de novo SL synthesis is required for tumor growth.  
The above proteomic and lipidomic analyses indicated that L-dKO mice 
preferentially accumulate GlcCer.  Furthermore, expression of the GlcCer 
synthesis enzyme GCS correlates with tumorigenicity (Liu, Han et al. 2000, 
Gupta, Bhinge et al. 2012, Kartal Yandim, Apohan et al. 2013, Liu, Hill et al. 
2013, Tyler, Johansson et al. 2015), and a GCS inhibitor blocks proliferation 
of leukemic (Huang, Tsai et al. 2011), lung cancer (Suzuki, Cao et al. 2016) 
pancreatic tumor (Wang, Wei et al. 2015) and HCC cells (Stefanovic, 
Tutusaus et al. 2016).  To determine whether accumulation specifically of 
GlcCer is important for tumor development in vivo, we knocked down GCS in 
hepatocytes in L-dKO mice.  AAV-shGCS or the control virus AAV-shScrmbl 
was injected into tail vein of 6 to 8 week-old L-dKO (n=6) and control mice 
(n=4).  Hepatic viral infection was confirmed by immunofluorescence (Figure 
S5H).  At 20 weeks of age, mice were euthanized, livers were dissected and 
tumors were counted.  Strikingly, chronic GCS inhibition reduced the number 
of liver tumors (Figure 2B).  Thus, GlcCer accumulation is required for tumor 
development. 
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mTOR promotes glycerophospholipid synthesis: Cardiolipin. 
The transcriptomic and proteomic analyses described above also suggested 
that mTOR promotes glycerophospholipid (PL) synthesis.  PL synthesis 
begins with the acylation of glycerol 3-phosphate by GPAT (Glycerol 3-
Phosphate Acyltransferase) to generate lysophosphatidic acid (LPA).  LPA is 
then converted to phosphatidic acid (PA) by AGPAT (Acylglycerol-3-
Acyltransferase).  PA is converted to diacylglyceride (DAG), by the PAP 
(Phosphatidic Acid Phosphatase, also known as LIPIN) family of enzymes.  In 
the so-called ‘Kennedy pathway’, DAG and choline or ethanolamine are 
condensed to yield phosphatidylcholine (PC) or phosphatidylethanolamine 
(PE), respectively (Gibellini and Smith 2010).  Alternatively, DAG is 
conjugated to CDP by CDS (CDP-DAG synthase) to produce the 
liponucleotide CDP-DAG.  CDP-DAG is used for the synthesis of 
phosphatidylinositol (PI), phosphatidylserine (PS), and cardiolipin (CL).  CLs 
are synthesized exclusively in the mitochondria (Schlame and Haldar 1993, 
Schlame, Rua et al. 2000) by PGS1 (Phosphatidylglycerophosphate 
Synthase 1).  PGS1 catalyzes the rate-limiting step in CL synthesis, 
condensing DAG and glycerol-3-phosphate to produce phosphatidylglycerol-
phosphate (PGP).  PGP is dephosphorylated by the PTEN-like mitochondrial 
phosphatase PTPMT1, generating a phosphatidylglycerol (PG) (Zhang, Guan 
et al. 2011).  Cardiolipin synthase (CRLS1) attaches PG to DAG, producing 
immature CL that is then remodeled in a series of reactions.  In the inner 
mitochondrial membrane (IMM) CLs stabilize the complexes of the electron 
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transport chain, thereby supporting oxidative phosphorylation (OxPhos) 
(Houtkooper and Vaz 2008, Duncan, Robinson et al. 2016). 
The transcriptomic and proteomic analyses described above and 
immunoblotting revealed increased hepatic expression of the PL synthesis 
enzymes GPAT, AGPAT, LIPIN, CDS, PGS1, CRLS1 and PTPMT1 in L-dKO 
mice (Figures 1C and 5A), suggesting increased synthesis of PLs, cardiolipin 
in particular.  Indeed, lipidomic analysis revealed elevated levels of the PLs 
phosphatidylinositol (PI), lysophosphatidylcholine (lysoPC) and cardiolipin 
(CL), with accumulation of CL being the most pronounced (Figure 4A).  
Importantly, the levels of PC and PE, both products of the Kennedy pathway, 
were reduced (Figure S6A, B).  The above suggests that cardiolipin is 
preferentially synthesized in L-dKO mice.  Thus, again consistent with the 
observed increase in fatty acid synthesis, L-dKO mice display increased 
hepatic synthesis of PLs, in particular via the biosynthetic pathway leading to 
cardiolipin (i.e., not the Kennedy pathway). 
 
Increased cardiolipin accumulation is associated with enhanced 
respiration. 
CLs stabilize complexes of the electron transport chain (ETC) thereby 
supporting oxidative phosphorylation (OxPhos) (Houtkooper and Vaz 2008, 
Duncan, Robinson et al. 2016).  Expression of ETC complexes was 
unchanged in L-dKO mice, compared to control littermates, as determined by 
immunoblot analysis and electron microscopy (EM) (Figure S6C-E).  However, 
hepatocytes from L-dKO mice exhibited hyper-tubular mitochondria and 
pronounced cristae, as determined EM analysis (Figures S6C and F).  The 
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hyper-tubular mitochondrial morphology was confirmed by staining L-dKO 
primary hepatocytes with the mitochondria specific dye MitoTracker-Red 
(Figures 5B, S5B).  To investigate mitochondrial function, OxPhos in 
particular, we measured the oxygen consumption rate (OCR) and 
mitochondrial reserve capacity of primary hepatocytes.  Primary hepatocytes 
from L-dKO mice displayed enhanced OxPhos and increased mitochondrial 
reserve capacity, compared to wild-type hepatocytes (Figure 5C).  Thus, 
increased cardiolipin accumulation correlates with enhanced mitochondrial 
function.  The increase in cardiolipin may increase mitochondrial function to 
sustain the enhanced metabolic needs of tumor cells.  
 
mTORC2 promotes FA, sphingolipid and cardiolipin accumulation. 
The above suggests that hyperactive mTOR signaling promotes lipid 
synthesis and cancer.  To confirm that tumor development is indeed mTOR 
dependent, 8 week-old L-dKO and control mice were chronically treated with 
the ATP competitive mTOR inhibitor INK128 (1 mg/kg/bw), or drug vehicle 
alone, for 12 weeks.  Chronic INK128 administration reduced mTOR 
signaling (mTORC1 and mTORC2) (Figure S6G), and prevented both liver 
damage  (Figure S6H) and tumor growth (Figure 6A), confirming that tumor 
development was mTOR dependent.  We note that chronic INK128 
administration also reduced hepatic TG content (Figure 6B) and hepatocyte 
size (Figure 6C). 
Hepatic mTORC1 and mTORC2 are activated in L-dKO mice.  To 
determine whether mTORC1 and/or mTORC2 signaling controls FA and lipid 
synthesis in L-dKO mice, we performed acute pharmacological inhibition 
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studies.  8 week-old L-dKO and control mice (n=4 per group) were treated 
acutely (24hrs) with rapamycin, INK128 or drug vehicle alone.  Acute 
rapamycin treatment inhibited mTORC1, as assessed by reduced S6-
Ser235/6, CAD-Ser1859 and ULK-Ser757 phosphorylation, and increased 
AKT-Ser473 phosphorylation, the latter due to inhibition of negative feedback 
from S6K (Figure S6I, mTORC2 panel).  Acute INK128 administration 
inhibited both mTORC1 (assessed as above) and mTORC2, as assessed by 
reduced AKT-Ser473, GSK-Ser21/9, and NDRG1-Thr346 phosphorylation 
(Figure S6I).  Acute INK128 treatment reduced both expression of ACC, 
FASN, and SCD1 (Figure 6D) and hepatic TG content in L-dKO mice, 
compared to INK128 treated control mice (Figure S7A).  We note that acute 
INK128 administration increased overall hepatic TG content in L-dKO and 
control mice compared to mice treated with drug vehicle alone (Figure S7A), 
likely due to enhanced lipolysis in adipose tissue as suggested by increased 
serum FA levels (Figure S7B) (Cybulski, Polak et al. 2009, Kumar, Lawrence 
et al. 2010).  Inhibition of mTORC1 alone (rapamycin) did not alter expression 
of hepatic FA synthesis enzymes or hepatic TG content (Figures S6I and 
S7A).  Thus, hepatic FA synthesis is activated by mTORC2. 
To confirm that mTORC2 promotes de novo FA and lipid synthesis, TG 
accumulation and liver cancer development, we deleted Rictor, an essential 
core component of mTORC2, in L-dKO mice.  Tsc1loxP/loxP; PtenloxP/loxP mice 
were crossed with RictorloxP/loxP mice expressing Alb-CRE, to generate triple 
knockout (L-TriKO) mice lacking Tsc1 Pten and Rictor (Figure S7C, D).  L-
TriKO mice were born according to Mendelian ratios and gained weight 
normally (not shown).  Immunoblot analysis of liver lysates revealed markedly 
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reduced mTORC2 activity in L-TriKO mice (Tsc1loxP/loxP; PtenloxP/loxP; 
RictorloxP/loxP; Alb-CRE) compared to littermate control mice (Tsc1loxP/loxP; 
PtenloxP/loxP; RictorloxP/loxP), as assessed by AKT-Ser473, GSK-Ser21/9, 
NDRG1-Thr346, and PKC-Thr638/641 phosphorylation; mTORC1 activity 
was not change in L-TriKO mice, as assessed by S6-Ser235/6, CAD-Ser1859 
and ULK-Ser757 phosphorylation (Figure S7E), thereby confirming the L-
TriKO mouse model.  Importantly, L-TriKO mice displayed reduced 
expression of ACC, FASN, SCD1 and their transcriptional activator SREBP1c 
(mature form), and reduced hepatic TG content (Figure 7A, B), compared to 
L-dKO mice.  Expression of the SL synthesis genes Spt and SMPD was also 
reduced in L-TriKO mice, compared to L-dKO mice (Figure 7C).  Similarly, 
immunoblotting of primary hepatocytes from knockout and control mice 
showed reduced CRLS1 expression in L-TriKO mice (Figure S7F).  Lipidomic 
analysis was also performed on liver lysates from L-TriKO, L-dKO and control 
mice (n=4/group), revealing reduced sphingolipid and glycerophospholipid 
levels, including GlcCer and CL(18:≤1), respectively, specifically in L-TriKO 
mice (Figures 4 and S5C).  Collectively, the above indicates that mTORC2 
activates de novo SL and PL synthesis. 
Importantly, in addition to reduced FA and lipid synthesis, L-TriKO mice 
also displayed reduced tumorigenicity (Figures 7D, E and S7G, H).  We note 
that the few tumors that arose in L-TriKO mice exhibited increased mTORC2 
activity, as assessed by immunohistochemical analysis of phosphorylated 
AKT473 (Figure S7I), suggesting that such tumors were due to 'escapers' in 
which Rictor was not deleted.  Thus, it is mTORC2 that is lipogenic and 
oncogenic in L-dKO mice.  
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Discussion 
 
Diverse mutations activate mTOR signaling to promote tumor development, 
but tumorigenic mechanisms downstream of mTOR signaling remain poorly 
defined, in particular for mTORC2.  We examined tumor development in an 
mTOR-dependent HCC mouse model (L-dKO).  We report that mTORC2 
promotes hepatosteatosis and ultimately tumor development via fatty acid 
(FA) and lipid synthesis. 
Similar to patients who develop NFALD that progresses to HCC (Postic 
and Girard 2008, Lambert, Ramos-Roman et al. 2014), L-dKO mice exhibit 
enhanced FA synthesis and thereby develop hepatosteatosis, liver damage 
and HCC (Figures 1A-E, S1A-G and S2A-H).  Knockdown of fatty acid 
synthase (FASN) specifically in hepatocytes blocked tumor development 
(Figures 2A-D and S4A, H).  Notably, FASN inhibition did not have a 
detrimental effect in wild-type hepatocytes, exposing a vulnerability specific to 
cancer cells.  Non-cancerous cells, which have reduced metabolic 
requirements, obtain sufficient amounts of FAs from the diet.  How do fatty 
acids promote tumor development?  First, FAs are necessary for the 
synthesis of lipids, which may in turn be necessary for tumorigenicity.  Indeed, 
we observed that lipid synthesis pathways, in particular de novo sphingolipid 
and glycerophospholipid synthesis, are also up-regulated in L-dKO mice 
(Figures 1C, 3A,B and 4A).  We note that the expression of lipid biosynthetic 
enzymes (SPT in particular) is up-regulated in various human cancer types 
(not shown).  Importantly, inhibition of the rate-limiting reactions in de novo 
SL synthesis or glucosylceramide synthesis prevented tumor development in 
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L-dKO mice, indicating that up-regulation of lipid synthesis is essential for 
tumorigenesis (Figures 2B, 3E, F and S5E).  Second, enhanced FA synthesis 
causes hepatosteatosis, a pathological accumulation of fatty acids, which 
may in turn promote inflammation (NASH) and HCC (Park, Lee et al. 2010, 
Wolf, Adili et al. 2014, Ma, Kesarwala et al. 2016).  Alternatively, FA could be 
used to produce the bioactive sphingolipid S1P leading to inflammation 
(Liang, Nagahashi et al. 2013, Taniguchi and Karin 2014).  Consistent with 
the notion that FAs are promoting tumor development via inflammation, L-
dKO mice exhibited up-regulated SPK1 (Sphingosine Kinase 1) and 
increased S1P levels which correlated with increased STAT3 phosphorylation 
(data not shown).  The role of inflammation in mTOR driven tumor 
development, and in particular its promotion by FAs, will require further study. 
How does up-regulation of sphingolipid (SL) and glycerophospholipid 
(PL) synthesis (in particularly of GlcCer and cardiolipin, respectively) promote 
cancer?  First, SL and PL are structural components of membranes and may 
thereby support tumor growth simply as building blocks.  Ceramide 
glycosylation by glucosylceramide synthease (GCS) yields the membrane 
component GlcCer, but also eliminates excess ceramide and its anti-
proliferative effect (Ogretmen and Hannun 2004).  Importantly, L-dKO mice 
preferentially accumulate GlcCer.  Thus, the essential role of GlcCer 
synthesis in tumorgenicity may be two-fold, one is the production of a building 
block, the other is to eliminate ceramide. Second, CL in the inner 
mitochondrial membrane (IMM) stabilizes complexes of the ETC thereby 
enhancing energy production and satisfying the increased metabolic needs of 
tumor cells (Schlame and Haldar 1993, Schlame, Rua et al. 2000, 
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Houtkooper and Vaz 2008, van der Bliek, Shen et al. 2013, Yu-Wai-Man, 
Carelli et al. 2014, Duncan, Robinson et al. 2016, Peck, Schug et al. 2016).  
Importantly, we observed increased CL synthesis and mitochondrial energy 
production in liver of L-dKO mice (Figure 4A, 5A-C and S6D, F).  Third, lipids 
provide second messengers in oncogenic signaling pathways (Hannun and 
Obeid 2008, Wymann and Schneiter 2008, Baenke, Peck et al. 2013).  For 
example, the glycerophospholipid PI is phosphorylated to generate 
phosphatidylinositol-3,4,5-triphosphate that mediates growth factor signaling.  
It remains to be determined whether the increased lipid synthesis observed in 
L-dKO mice is affecting second messenger levels in oncogenic signaling 
pathways. 
How does mTORC2 regulate FA synthesis?  L-dKO mice display 
increased levels of mature SREBP1c and increased expression of SREBP1c 
target genes Acc, Fasn, Scd1 and Elovl6 (Figures 1A, C and S2E).  
Pharmacological or genetic ablation of mTORC2 signaling in L-dKO mice (L-
TriKO) prevented SREBP1c processing, decreased Acc, Fasn, and Scd1 
expression, and thereby reduced de novo FA synthesis (Figures 6D and 7A, 
B).  Thus, mTORC2 promotes de novo FA synthesis via SREBP1c, as shown 
previously (Hagiwara, Cornu et al. 2012, Kenerson, Subramanian et al. 2015).  
Alternatively, mTORC2 or its effectors may phosphorylate FA synthesis 
enzymes directly, as recently proposed for ACLY (Chen, Qian et al. 2016) 
(Figures 1A and 6D).  Finally, mTORC2 increases expression of the fatty acid 
transporter CD36 (Figure 1A), an effect that was blocked in L-TriKO mice 
(Figure 7A), allowing up-take of FA from the bloodstream. 
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We note that mTORC1 has also been proposed to stimulates FA 
synthesis (reviewed in (Ricoult and Manning 2013)).  For example, mTORC1 
contributes to de novo FA synthesis in breast cancer cell lines (Ricoult, 
Yecies et al. 2015).  However, mTORC1 alone is insufficient to promote de 
novo FA synthesis in vivo.  First, liver specific Tsc1 knockout mice 
(constitutively active mTORC1) are protected from age and diet induced 
hepatosteatosis (Kenerson, Yeh et al. 2011, Yecies, Zhang et al. 2011, Cornu, 
Oppliger et al. 2014, Kenerson, Subramanian et al. 2015).  Second, liver 
specific Raptor knockout mice (abrogated mTORC1 activity) exhibit unaltered 
hepatic FA levels, even when fed a high fed diet (Umemura, Park et al. 2014).  
Third, activation of mTORC1 in the absence of mTORC2 signaling is 
insufficient to activate expression of FA synthesis genes (Titchenell, Quinn et 
al. 2016).  Thus, mTORC2 may play a more important role than mTORC1 in 
hepatic FA synthesis. 
How does mTORC2 activate lipid synthesis?  We observed that mTORC2 
controls expression of some lipid synthesis genes, suggesting that the 
mechanism is at the level of transcription (Figure 7A, C).  However, mTORC2 
is functionally at ER-mitochondria contact sites known as MAM (Mitochondria 
Associated Membrane) (Betz and Hall 2013, Betz, Stracka et al. 2013), 
where PL synthesis occurs.  Thus, mTORC2 or its kinase effectors could also 
directly phosphosphorylate and activate PL synthesis enzymes.  For example, 
pACLY-Ser455 activation in skeletal muscle was mediated by AKT and 
promoted CL synthesis (Das, Morvan et al. 2015).  The mechanism by which 
mTORC2 activates lipid synthesis remains to be determined.  
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Does mTORC1 play a role in in lipid synthesis in L-dKO mice?  mTORC1 
stimulates pyrimidine biosynthesis via phosphorylation of CAD and 
transcriptional activation of the pentosphosphate pathway (Ben-Sahra, 
Howell et al. 2013, Robitaille, Christen et al. 2013).  The pyrimidines uridine 
diphosphate (UDP) and cytidine diphosphate (CDP) are required for the rate-
limiting reactions in GlcCer and PL synthesis, respectively.  L-dKO mice 
display increased CAD phosphorylation (Figure S6I and S7E).  Thus, our 
data favor a model in which mTORC1 and mTORC2 converge on lipid 
synthesis to drive tumor development. 
Collectively, we provide mechanistic insights for oncogenic mTORC2 in 
promoting FA and lipid synthesis.  Lipids are required for tumor growth, as 
macromolecules, but also to support mitochondrial function to match 
increased energy demand.  Inhibition of FA or lipid synthesis pathways kills 
cancer cells, thus exposing a cancer-specific vulnerability that can be 
exploited for the rational design of targeted cancer drugs. 
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Experimental Procedures 
 
Data analysis.  Statistical analysis and data plotting was performed using 
Prism Graph Pad 6.0.  Statistical significance was defined as <0.05.  An 
unpaired Student’s t-test was used to determine differences among two 
groups.  Significance was judged when p-value is less than 0.05.  Error bars 
in figures represent standard error of the mean (SEM).  Kaplan-Meier method 
was used for survival analysis. 
 
Animals.  Liver-specific tuberous sclerosis complex 1 (Tsc1) and 
phosphatase and tensin homolog (Pten) double knockout mice were obtained 
by crossing Tsc1lox/lox mice (Kwiatkowski, Zhang et al. 2002) with Ptenlox/lox 
mice (Horie, Suzuki et al. 2004, Stiles, Wang et al. 2004) to transgenic mice 
expressing Cre recombinase under the control of the hepatocyte-specific 
albumin promoter (Alb-Cre) (Postic and Magnuson 2000), to generate liver 
specific double knockout (L-dKO) mice.  Tsc1loxP/loxP; PtenloxP/loxP mice were 
crossed to Rictor loxP/loxP; Alb-Cre (Cybulski, Polak et al. 2009) to obtain 
(Tsc1loxP/loxP; PtenloxP/loxP; Rictor loxP/loxP; Alb-Cre) liver specific triple knockout 
(L-TriKO mice) mice.  As controls, male littermate Tsc1loxP/loxP; PtenloxP/loxP 
mice or Tsc1loxP/loxP; PtenloxP/loxP; Rictor loxP/loxP mice (which do not express  the 
Cre-recombinase) were used.  Mice were on mixed genetic background 
(C57BL/6J, 129/SvJae, BALB/cJ).  Both L-dKO mice (Tsc1loxP/loxP; 
PtenloxP/loxP; Alb-Cre) and L-TriKO (Tsc1loxP/loxP; PtenloxP/loxP; Rictor loxP/loxP; Alb-
Cre) mice were born viable at the expected Mendelian ratio and displayed 
normal fertility.  PCR genotyping for Tsc1 (Kwiatkowski, Zhang et al. 2002) 
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Pten (Horie, Suzuki et al. 2004, Stiles, Wang et al. 2004) and Rictor (Cybulski, 
Polak et al. 2009) and Cre was performed as described.  Mice were 
maintained under temperature and humidity-controlled conditions, lights on at 
6:00 AM and off at 6:00 PM.  In all experiments, mice were sacrificed at 
6:00am and were ad-libitum fed, unless mentioned otherwise.  All of the 
experiments were conducted on male mice.  All experiments were performed 
in accordance with federal guidelines and were approved by the Kantonales 
Veterinaeramt of Kanton Basel-Stadt. 
 
Whole-Body Metabolic Analysis.  RER (Respiratory Exchange Rate), 
locomotor activity and food consumption were measured in 30 minute-
intervals, for the indicated time using a comprehensive laboratory animal 
monitoring system (CLAMS, Linton Instrumentation and Columbus 
Instruments).  Measurement was performed after 24 hrs of acclimatization.  
Mice had free access to food and water. 
 
Virus Administration.  To determine virus liver tropism, 5*10^11 viral genome 
of AAV8-U6-CMV-RFP, AAV-DJ-U6-CMV-eGFP and AAV-DJ-Albumin-eGFP 
was injected into tail veins of wild-type (control).  For viral knockdown studies, 
AAV-DJ-albumin-shFASN-RFP, AAV-albumin-shGCS-RFP and AAV-
albumin-shScrmble-RFP (purchased from Vector BioLabs) were used.  Virus 
was administrated to mice by tail-vein injection (5*10^11 vg, unless mentioned 
otherwise).  To validate virus action mice were sacrificed one-month post 
injection (short-tem) livers were further used for biochemical analysis.  To 
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assess the effect on liver tumors development mice were sacrificed about 
three months post infection. 
 
OCR and ECAR measurements.  Measurements were performed with an 
XF96 Extracellular Flux Analyzer (Seahorse Bioscience of Agilent) following 
manufacturer instructions.  2×105 hepatocytes were seeded into 96 culture 
plate (Seahorse Bioscience of Agilent) overnight or measured 1hr post-
seeding.  Media was exchanged prior to the measurement. 
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Figure 1.  L-dKO mice develop HCC and exhibit enhanced de novo fatty acid 
and lipid synthesis  (A)  Immunoblot analysis of liver extracts from ad-libitum 
fed 4, 8, 12, and 20 week-old L-dKO mice and littermate controls, for the 
indicated proteins.  Each lane consists of a mixture of liver extracts obtained 
from six mice.  (B)  Representative staining of hepatic tumors from L-dKO 
mice and tumor-free control mice. Hematoxylin and Eosin (H&E), Sirius Red 
(SR), Periodic Acid Schiff (PAS), and FASN (Immunohistochemistry).  
Asterisks and arrows indicate HCCs and HCC margins, respectively.  Scale 
bar 50µm (C)  Relevant lipid biosynthetic enzymes are depicted.  Up-or 
down-regulated enzymes in the proteome analyses of livers from young mice 
(4, 8 and 12 weeks of age, n=6 per time point) or proteome and transcriptome 
analyses of tumors (20 weeks of age, 12 dissected tumors from 3 mice) or 
immunoblotting are color coded:  white, not quantified (n.q.) in transcriptome 
or proteome;  blue, down-regulated in transcriptome or proteome;  red, up-
regulated in transcriptome or proteome.  Phosphorylation site in a red box 
was up-regulated in phosphoproteomics  (D)  Representative images of 
frozen liver sections from 20 week-old L-dKO mice (tumors) and a tumor-free 
control, stained with Oil-Red-O (ORO) (n=3).  Number and size (area) of 
hepatic lipid droplets were quantified using FIJI (a.u. arbitrary unit).  (E)  
Hepatic triglyceride (TG) content from ad-libitum fed L-dKO and control mice 
(at least n=4 per group).  pH/E, ethanolamine-1-phosphate and C16-fatty 
aldehyde.  To determine statistically significant differences unpaired 
Student’s t-test was used.  Error bars represent SEM. 
 
 
	   64 
 
Figure 2.  FASN or GCS inhibition prevents tumor development in L-dKO 
mice.  (A)  Number of liver tumors in L-dKO mice treated with orlistat or the 
drug vehicle alone.  (B)  Number of liver tumors in L-dKO mice treated with 
AAV-shScrmbl, AAV-shFASN or AAV-shGCS.  (C)  Representative 
immunofluorescence images from livers of L-dKO mice treated with AAV-
shFASN or AAV-shScrmbl control.  White circles designate hepatocytes 
successfully infected with the indicated virus. Nuclei, blue (DAPI);  Ki67, red;  
AAV (virus), green.  (D)  Quantification of the number of Ki67 positive cells in 
livers from L-dKO mice infected with AAV-shFASN or AAV-shScrmbl control, 
per 10X magnification field (n=3).  To determine statistically significant 
differences unpaired Student’s t-test was used.  Data represent mean ± SEM. 
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Figure 3.  mTOR promotes de novo sphingolipid synthesis and thereby tumor 
development.  (A)  Relative hepatic mRNA level (normalized to cyclophilinD) 
in 4, 8 and 20 week-old L-dKO and control mice (n=6 per group), for the 
indicated genes.  (B)  Hepatic sphinganine levels in livers of 4, 8, 12 and 20 
week-old mice (n=6 per group).  Data represented as the ratio of L-dKO over 
age-matched control.  (C)  Hepatic serine levels in livers of 4, 8, 12 and 20 
week-old mice (n=6 per group).  Normalized (norm.) to total amino acids (AA).  
(E)  Number of liver tumors in L-dKO mice after chronic myriocin treatment.  
(F)  Scatter plot of the major lipid species significantly regulated in livers from 
myriocin treated mice (L-dKO vs. control), as compared to the drug vehicle.  
Glucosylceramide lipid species are indicated in red.  Black line indicates the 
significant from the non-significant alterations, for threshold of 0.75 Log-Fold 
change.  To determine statistically significant differences unpaired Student’s 
t-test was used.  Data represent mean ± SEM. 
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Figure 4.  L-dKO mice accumulate sphingolipids and glycerophospholipids in 
the liver.  (A)  Enrichment of the indicated lipid subclasses (Z-Score, Binomial 
Proportions Test), for the indicated genotypes.  Data expressed as the ratio 
of L-dKO over age-matched control (n=6 per time point);  L-TriKO mice over 
L-dKO mice (20 week old) (n=4).  Abbreviations: GlcCer, Glucosylceramide;  
GlcCer-OH, hydroxyglucosylceramide;  SM, Sphingomyelin;  CL(18:≤1) or 
CL(18:>1),  Cardiolipin with the indicate desaturation;  DHCer, 
Dehydroceramide;  Cer, Ceramide;  GlcDHCer, glucosyldehydroceramide;  
PS, Glycerophosphoserine;  DHCer-OH, hydro-deoxy-ceramide,  GlcDHCer-
OH, Gluc-hydro-deoxy-ceramide,  PI, Glycerophosphoinositol,  SM-OH, 
Hydro-sphingomyelin,  CerP, Phospho-ceramide,  Cer-OH, hydro-ceramide;  
LysoPC, Lysophosphatidylcholine. 
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Figure 5.  mTOR promotes cardiolipin synthesis and oxidative 
phosphorylation in hepatocytes.  (A)  Immunoblot analysis of liver extracts 
from 4, 8, 12, and 20 week-old L-dKO mice and control littermates, for the 
indicated proteins.  Each lane consists of a mixture of liver extracts obtained 
from six mice.  (B)  Representative images of primary hepatocytes perfused 
from 8 week-old L-dKO and control mice.  MitoTracker (red) indicates 
mitochondria.;  white arrows indicate tubular mitochondrial networks.  Nuclei, 
blue (DAPI);  Scale bar 10µm.  Acquired using LSM800 AriScan confocal 
microscope.  (C)  Oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) analyses of primary hepatocytes perfused from 8 
week-old L-dKO and control mice.  Dashed lines indicate the time a given 
compound was added;  Backg, background contains no cells;  Pcyt1a, 
phosphate cytidylyltransferase 1, choline, alpha; data represent mean ± SEM. 
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Figure 6.  mTOR promotes tumor development in L-dKO mice.  (A)  Number 
of liver tumors in L-dKO mice treated with INK128 (INK) or the drug vehicle 
(Veh.).  (B)  Hepatic triglyceride (TG) content of L-dKO and control mice 
treated with INK128 or the drug vehicle (n=7 per group).  (C)  Cell-size 
expressed as area (a.u. arbitrary unit) calculated using FIJI from scanned 
histological samples stained for H&E.  (D)  Immunoblot analysis of liver 
extracts from 8 week-old L-dKO and control mice (n=4 per group) acutely 
(24hrs) treated with rapamycin (Rapa), INK128 or drug vehicle alone (Veh> 
and Veh#  treated with rapamycin or INK128 vehicle control, respectively), for 
the indicated proteins.  Values are expressed as mean ± SEM. 
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Figure 7.  mTORC2 promotes fatty acid and lipid accumulation and 
carcinogenesis.  (A) Immunoblot analysis of liver extracts from 20 week-old 
L-dKO, L-TriKO and control mice (n=4 per group;  Cntl> and Cntl #  are 
Tsc1loxP/loxP; PtenloxP/loxP; and Tsc1loxP/loxP; PtenloxP/loxP; RictorloxP/loxP, 
respectively), for the indicated proteins.  (B)  Hepatic triglyceride (TG) content 
of L-dKO, L-TriKO and pulled controls (n ≥ 4 per group).  (C)  Relative mRNA 
level (normalized to cyclophilinD) of the indicated genes in 20 week-old L-
dKO (n=6), L-TriKO (n=4) and control (n=8) mice.  (D) Number of 
macroscopic liver tumors detected in L-dKO and L-TriKO mice  (E)  Kaplan 
Meier survival curve of L-dKO and L-TriKO mice.  (**** p<0.0001 for both 
Mantel-Cox and Gehan-Breslow-Wilcoxon tests, ## p<0.0008 Mantel-Cox 
and p= 0.0021 Gehan-Breslow-Wilcoxon tests).  Error bars represent SEM. 	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Figure S1, related to Figure 1.  Hepatic mTOR activation induces tumor 
development.  (A)  Representative images of livers from 4, 8, 12 and 20 
week-old L-dKO mice;  white arrows indicates liver tumors.  (B)  Liver weight 
(LW) to body weight (BW) ratio (percentage) of L-dKO mice and age-matched 
control mice for the indicated time-points.  (C)  Total body weight of 4, 8, 12 
and 20 week-old L-dKO and control mice (n ≥ 10 per time point)  (D)  ALT 
(alanine aminotransferase), AST (aspartate aminotransferase) and LDH 
(lactate dehydrogenase) (n ≥ 4) serum levels, in unit per liter (U/L)  (E)  
Relative mRNA level (normalized to cyclophilinD) of afp and aldh in liver 
lysates from 8 week-old L-dKO and control mice (n ≥ 4).  (F)  Representative 
hematoxylin and eosin (H&E) images from 8 week-old L-dKO and control 
mice;  white arrows, hepatocytic-ballooning reminiscent of lipid accumulation 
(macrosteatosis);  white circle, choleangiocytic proliferation  (G)  
Representative immunofluorescence images of BrdU incorporation assessed 
in tumors from 16 week-old L-dKO and non-tumor control.  To determine 
statistically significant differences unpaired Student’s t-test was used.  Data 
represent mean ± SEM. 
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Figure S2, related to Figure 1.  (Phospho)proteomic analysis indicates 
enhanced fatty acid and lipid metabolism in L-dKO mice.  (A)  Heat-maps of 
the unsupervised hierarchical clustering using Euclidian distance of proteome 
and  (B)  phosphoproteome performed on snap-frozen liver samples from 4, 8 
and 12 week-old L-dKO and control mice.  The corresponding pathway 
enrichment analysis was performed for proteins  (C)  and phosphosites  (D)  
down- or up- regulated in all three time points (dark lines).  Lipid metabolic 
pathways are marked in yellow.  (E), (F)  Relative hepatic mRNA level 
(normalized to cyclophilinD) of the indicated genes from 8 week-old L-dKO 
and control mice (n ≥ 4).  (G)  Representative H&E images from 8 week-old 
L-dKO and control mice.  Red circle marks a hepatocyte with the diameter 
indicated.  (H)  Area calculated from H&E stained liver samples from 4, 6, 8, 
10 and 12 L-dKO and control mice.  Area is relative to the image 
magnification (a.u. arbitrary unit).  (I)  Hepatic triglyceride (TG) content from 
overnight fasted L-dKO and control mice (n ≥ 6 per group).  To determine 
statistically significant differences unpaired Student’s t-test was used.  Data 
represent mean ± SEM. 
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Figure S3, related to figure 1.  L-dKO mice exhibit whole body cachexia-like 
effects.  (A)  RER (Respiratory Exchange Ratio, unit-less ratio of the rate of 
CO2 production to the rate of O2 consumption)  (B)  food consumption and  
(C)  movement (ambulatory) of 12 and 20 week-old L-dKO and control mice 
measured over 72hrs (n=8 control, n=7 L-dKO).  The last 48 hours of 
measurement were used for quantification.  Sums of light or dark phases are 
also calculated.  (D)  Longitudinal whole-body fat composition analyses 
(EchoMRI) of live L-dKO and control mice (n=8 control, n=7 L-dKO).  (E)  
Percent of epididymal white adipose tissue (eWAT) and subcutaneous WAT 
mass (normalized to the body weight (BW)) of 8 and 20 week-old L-dKO and 
control mice (n ≥ 6 per group).  (F)  Percent of skeletal muscle mass 
(normalized to the body weight) of 8 and 20 week-old L-dKO and control mice.  
Sol, Soleus muscle;  Quad. f., Quadriceps Femoris muscle;  Gastroc., 
Gastrocnemius muscle (n ≥ 6 per group); BW, body weight.  (F)  Relative 
mRNA level (normalized to cyclophilinD) from livers of 8 week-old L-dKO and 
control mice (n=6 per group), for the indicated genes.  (H)  LDL and HDL 
level in serum of 8 week-old L-dKO and control mice (n=4 per group).  To 
determine statistically significant differences unpaired Student’s t-test was 
used.  Data represent mean ± SEM. 
  
	   79 
 
 
 
	   80 
Figure S4, related to figure 2.  FA synthesis is required for tumor 
development.  (A)  Representative images of livers from L-dKO mice treated 
with orlistat or the drug vehicle alone (B)  and number of lipid droplets 
quantified from histological sections (not shown).  White arrows indicated 
HCCs.  (C)  Body weights (BW) and liver weights (LW)  (D)  and immunoblot 
from liver lysates from L-dKO and control mice treated with orlistat (Orli.) or 
the drug vehicle (Veh.) alone.  (E)  The indicated adeno-associate viruses 
(AAV) were injected into tail veins of wild-type mice; control mice were 
injected with PBS.  The expression of GFP or RFP was from a U6 or albumin 
promoter (as indicated).  mRNA expression of GFP or RFP was assessed by 
quantitative PCR.  The absolute (not normalized) Ct values are depicted, for 
the indicated tissue.  n.d., not detected.  (F)  mRNA fasn expression relative 
to RFP expression of livers of mice infected with AAV-shFASN or AAV-
shScrmbl.  (G)  Immunoblot analysis of liver extracts from mice (one per lane) 
infected with different viral genomes of AAV-shFASN and AAV-shScrmbl 
control, for the indicated proteins.  Pon. S, Ponceau S.  (H)  Representative 
immunofluorescence images of livers from L-dKO mice infected (tail vein) 
with AAV-DJ-Albumin-shFASN-RFP (AAV-shFASN) or AAV-shScrmbl.  
shFASN or AAV-shScrmbl were expressed from the albumin promoter.  
White circles marks AAV-shScrmbl infected Ki67 positive hepatocytes.  
Dashed circle marks a non-infected hepatocyte that is Ki67 positive.  Nuclei, 
blue (DAPI);  Scale bar 100µm.  (I)  Representative immunofluorescence 
images of livers from L-dKO mice infected (tail vein) with AAV-shFASN.  Neg. 
cntl, negative control was injected with PBS.  Scale bar 10µm.  Images 
obtained using ‘DeltaVision Core’ widefield microscope.  Images were 
deconvoluted.  Data represent mean ± SEM. 
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Figure S5, related to figure 3.  De novo sphingolipid synthesis is required 
for tumor development.  (A)  mRNA expression levels in livers from 4, 8 and 
20 week-old L-dKO and control mice (n=6 per genotype), for the indicated 
genes.  SPK1, sphingosine kinase;  SMPD3,  neutral sphingomyelinase;  
SMPD1, acid sphingomyelinase.  (B)  Representative immunofluorescence 
images of primary hepatocytes from L-dKO or control mice.  Nuclei, blue 
(DAPI);  SPT, serine palmitoyltransferase;  GCS, glucosylceramide synthase;  
MitoTrack, MitoTracker Red mitochondria.  Scale bar 10µm.  LSM800 
AriScan confocal microscope.  (C)  Representative immunofluorescence 
images of livers from 8 week-old and 20 week-old (tumor) L-dKO, L-TriKO 
and control mice.  GlcCer, glucosylceramide; nuclei, blue (DAPI);  scale bar 
10µm.  (D)  Hepatic glutamine and alanine levels from 4, 8, 12, and 20 week-
old L-dKO and control mice normalized to total amino acids (AA).  (E)  
Principal-component analysis (PCA) of lipidomics from L-dKO and control 
mice treated with myriocin or the drug vehicle alone.  PCA analysis showed a 
clear discrimination between L-dKO and control mice, driven by principal 
component 1 (dashed circles).  Principle component 2 drove the separation 
between myriocin and vehicle treated groups (closed circle).  (F)  Immunoblot 
analysis of liver extracts from L-dKO and control mice treated with myriocin or 
the drug vehicle only, for the indicated proteins.  (G)  Body weights (BW) and 
liver weights (LW) of L-dKO and control mice treated with myriocin (Myr.) or 
the drug vehicle (Veh.) alone.  (H)  Representative immunofluorescence 
images of livers from L-dKO mice infected (tail vein) with AAV-shGCS.  Scale 
bar 10µm.  ‘DeltaVision Core’ widefield microscope.  Images were 
deconvoluted.  Values are expressed as mean ± SEM. 
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Figure S6, related to figures 4 to 6.  Enhanced cardiolipin accumulation and 
mitochondria function in mTOR-activated tumors  (A)  Lipid subclasses 
depleted in livers of L-dKO mice or L-TriKO mice.  Data expressed as the 
ratio of L-dKO over age-matched control (n=6 per time point);  L-TriKO mice 
over L-dKO mice (20 week old) (n=4).  (B)  Binomial Proportion Test formula 
used for enrichment calculation.  (C)  Immunoblot analysis of liver extracts 
from 4, 8, 12 and 20 week-old L-dKO and control mice (6 mice per lane), for 
the electron transport chain components (c. complex;  sub. subunit;  ATP sy. 
α, ATP synthase α).  Each lane consists of a mixture of liver extracts obtained 
from six mice.  (D)  Representative electronmicrographs of hepatocytes from 
8 week-old L-dKO and control mice (n=3).  Asterisks and arrows indicate lipid 
droplets and mitochondria, respectively. Scale bar 1000nm  (E)  Number of 
mitochondria in hepatocytes from L-dKO and control mice.  Quantified from 
electron electronmicrographs (n=3).  (F)  Dark arrows indicates the prominent 
mitochondrial cristae observed in hepatocytes from L-dKO, compared to age-
matched control. Scale bar 500nm.  (G)  Immunoblot analysis of liver lysates 
from L-dKO and control mice chronically treated with INK128 (INK) or the 
drug vehicle alone (veh.), for the indicated proteins.  (n ≥ 2 per lane).  (H)  
ALT, AST and LDH levels (U/L) in serum from L-dKO mice treated chronically 
with INK or the drug vehicle alone.  (I)  Immunoblot analysis of liver extracts 
from 8 week-old L-dKO and control mice (n=4 per group) acutely (24hrs) 
treated with rapamycin (Rapa), INK128 or drug vehicle alone (Veh> and Veh#  
treated with rapamycin or INK128 vehicle control, respectively), for the 
indicated proteins.  Error bars represent SEM. Abbreviations:  EtherPC, 
Ether-phosphatidylcholine;  EtherPE, Ether-phosphatidylethanolamine;  PC, 
phosphatidylcholine;  PE, phosphatidylethanolamine;  DHSM, 
dihydrosphingomyelin;  SM-OH, sphingomyelin-OH;  EtherPS, Ether-
phosphatidylserine;  LysoPE, Lyso phosphatidylethanolamine;  SM, 
sphingomyelin;  PS,  phosphatidylserine;  CL(18:>1),  Highly desaturated 
Cardiolipin;  Cer, Ceramide;  Cer-OH, Ceramide-OH;  CerP,  ceramide 
phosphate.  
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Figure S7, related to figure 7.  mTORC2 controls hepatic FA and lipid 
synthesis.  (A)  Hepatic triglyceride (TG) content and  (B)  serum fatty acids 
(FA) from 8 week-old L-dKO and control mice (n=4 per group) acutely (24hrs) 
treated with rapamycin (Rapa), INK128 or drug vehicle alone (pulled n=8).  
(C)  Generation of triple mutant mice (floxed genes annotated; Alb, albumin 
promoter )  (D)  Representative DNA gels from L-TriKO mice for the indicated 
genes and Cre (Asterisk marks a Cre negative sample).  (E)  Immunoblot 
analysis from liver extracts from 20 week-old L-dKO, L-TriKO and the 
respective control mice (n=4, 2 mice per lane) (cntl> is Tsc1loxP/loxP;PtenloxP/loxP;  
cntl#  is Tsc1loxP/loxP;PtenloxP/loxP; RictorloxP/loxP).  (F)  Immunoblot analysis of 
extracts from hepatocytes (H) and non-hepatocyte (NH) cell fractions from 
perfused livers from 8 week-old L-dKO, L-TriKO and control mice (WT), for 
the indicated proteins.  Coronin 1 and albumin are immune cell marker and 
hepatocyte marker, respectively.  (G)  Representative Hematoxylin and Eosin 
(H&E) and Periodic Acid-Schiff histological analyses from L-dKO, L-TriKO 
and control mice. (H)  Representative images of livers from L-TriKO, L-
dKO(Rictor-/+) and control mice.  (I)  Immunohistochemistry analysis of livers 
from 30 week-old L-TriKO with tumors and an age-matched non-tumor 
control.  Arrows indicates pAKT-Ser473 positive regions (tumors).  Values are 
expressed as mean ± SEM. 
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Extended Experimental Procedures 
 
Pharmacological treatments.  INK128 (Intellikine, Inc) or the drug vehicle 
alone was given by orally route (1 mg/kg/bw).  INK128 was dissolved in 5% 
1-methyl-2-pyrrolidionone, 15% polyvinylpyrrolidone K30, and 80% water, as 
described (Hsieh, Liu et al. 2012).  8-week-old L-dKO mice and littermate 
controls (n=7 per group) were treated with INK128 or with the drug vehicle, 
every second day for 12 weeks.  Rapamycin (LC Laboratories) was dissolved 
as published (Cornu, Oppliger et al. 2014) in 5% (vol/vol) PEG-400, 4% 
(vol/vol) ethanol, and 5% (vol/vol) Tween 80, and was injected intra-
peritoneally (i.p.).  For acute mTOR inhibition studies, rapamycin or INK128 
or the drugs vehicles were administered to 8-10 weeks-old L-dKO and 
littermate controls (n=4 per group), twice (6 am and 6pm) over 24 hours at 
doses described above.  Orlistat (Xenical) was orally given (120mg/kg) to 6-8 
week-old L-dKO mice and littermates controls (n=4 per group) daily for 10 
weeks, as described (Sounni, Cimino et al. 2014).  Myriocin was formulated 
as described (He, Johnson et al. 2004).  Myriocin or the drug vehicle was i.p. 
administered (0.03 mg/kg/bw) to 6-8 week-old L-dKO mice and littermate 
controls (n=5 myriocin, n=4 vehicle), every second day.  For tumor burden 
assessment, mice were sacrificed (~ 20 weeks of age) and their livers 
removed.  Subsequently, externally visible tumors (>0.2 mm) were counted 
by stereomicroscopy.  To evaluate cell proliferation in tumors, 16 week-old L-
dKO and littermate control mice were i.p. injected with 100 mg/kg BrdU 
(Roche) once a day, at 18:00pm for three days.  At 6:00am of the forth day, 
mice were sacrificed and livers were removed.  Liver lobes, containing both 
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tumor and non-tumor regions, were fixed in 4% paraffin and were then used 
for immunofluorescence imaging using the BrdU in situ detection kit (Roche). 
 
Serum parameters.  Prior to liver dissection, blood was collected from the 
inferior vena cava using a 23-gauge needle.  Blood was placed immediately 
into a heparin-coated tube (BD microtainer) to obtain plasma.  Subsequently, 
50ul of plasma was diluted three times and loaded to a COBAS (Roche) 
analyzer.  Serum parameters, including circulating transaminases (ALT, AST), 
LDH, albumin, as well as serum lipids levels (LDL, HDL) were measured. 
 
Isolation of primary cells and cell culture.  For isolation of primary mouse 
hepatocytes 8-12 week-old L-dKO and littermate controls were used.  
Primary hepatocytes were obtained by liver perfusion.  Shortly, peritoneal 
cavity was opened and the inferior vena cava was cannulated using a 23-
gauge needle catheter.  Cannula was clamped using a surgical clip.  The liver 
was then perfused with pre-warmed (37c) Ca2+ and Mg2+ free-HBSS 
containing EGTA (1 mM), at a rate ranging from <5 to 10ml/min prior to chest 
dissection.  The aorta was ligated followed and the portal vein was transected.  
Liver was then perfused with pre-warmed (37c) HBSS with Ca2+ and Mg2+ 
containing collagenase digestion solution (collagenase type II (C6885 
SIGMA) and DNase I (10 µg/mL)), at a rate of 7.5ml/min.  Subsequently, the 
perfused and digested liver was carefully dissected and placed in a petri dish 
containing ice-cold HBSS.  Glisson capsule was gently teased with forceps to 
get the cell suspension.  Cell suspension was filtered through gauze to 
remove undigested tissue and connective tissue, followed by 5 min 
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centrifugation 650 × g.  Thereafter, re-suspended with HBSS and followed by 
3 min at 35 × g centrifugation to obtain parenchymal cells (hepatocytes, 
pellet) and non-parenchymal cells (non-hepatocytes, supernatant).  
Parenchymal cell suspensions, containing vital hepatocytes, were used for 
culture.  Briefly, hepatocytes were resuspended in pre-warmed culture media 
(DMEM high glucose with 10% fetal bovine serum (FBS). 
 
Quantitative PCR.  Total RNA was isolated from ∼50 mg of mouse livers. 
Liver samples were homogenized for 30 sec bead beating in lysing matrix D 
tubes (Q-Biogene) containing 1 mL of TRIzol reagent (Sigma).  After the 
chloroform extraction and centrifugation, samples were mixed with 600 µL of 
70% ethanol, and the extraction was continued with the RNeasy kit (Qiagen).  
DNase digestion was performed using RNase-Free DNase Set (Qiagen).  
cDNA synthesis was performed using SuperScript III reverse transcriptase 
(Invitrogen).  Semi-quantitative real-time PCR was done using the fast SYBR 
green mix (Applied Biosystems) and quantitated using Applied Biosystems 
StepOnePlus Real-Time PCR Systems (Applied Biosystems).  Duplicate (or 
triplicate) runs of each sample were normalized to cyclophilin D to determine 
relative expression levels.  Values plotted represent averages from at least 
four different animals.  The sequences for the primer pairs used in this study 
are listed in Table S7.  
 
Immunoblot.  Mouse livers were rapidly isolated, flash-frozen into liquid 
nitrogen, and stored at -80 °C.  For protein extraction liver tissues were 
homogenized using a polytron, in ice-cold lysis buffer (100 mM Tris (pH 7.5), 
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2 mM EDTA, 2 mM EGTA, 0.5 M mannitol) supplemented with 1% Triton X-
100, protease and phosphatase inhibitor mixture tablets (Roche).  Lysates 
were centrifuged at 10,000 × g for 10 min at 4 °C, afterwards pelleted cell 
debris was removed.  This was repeated three times.  Total protein 
concentration was assessed (BCA Protein Assay; Thermo Scientific). 
Subsequently, 20 µg of proteins were loaded on SDS/PAGE and transferred 
to a nitrocellulose membrane.  The following antibodies were used for 
immunoblotting: TSC1 (A300-316A), PTEN (CS #9188), p70 S6 Kinase (CS 
#2708), Phospho-p70 S6 Kinase (Thr389) (CS #9234), ULK1 (CS #6439), 
Phospho-ULK1 (Ser757) (CS #14202), CAD-pSer1859, GSK3α-pSer9/21 
(CS #5676), SREBP1c (SC-8984), SCD1 (CS #2794), ACC (CS #3662), 
FASN (CS #3180), phospho-ACLY (Ser455), ACLY (CS #13390), Phospho-
ACLY (Ser455) (CS #4331), CD36 (NB400-144), GCS (Bioss,	  bs-0701R or 
Abcam, ab197369), CAD (Bethyl, BP301-374), NDRG1 (CS#5196), phospho-
NDRG1 (Thr346) (CS#3217). AKT (CS#9272), phospho-AKT (Thr308) 
(CS#4056), phospho-AKT (Ser473) (CS#9271), S6 ribosomal Protein 
(CS#2217), phospho-S6 ribosomal Protein (Ser235/236) (CS#4856), and α-
actin (MAB1501) from Millipore.  For detection, Supersignal west pico 
chemiluminescent substrate or Supersignal west femto maximum sensitivity 
substrate (Pierce) was used. 
 
Histology and Immunostainings.  Mice were euthanized, livers quickly 
dissected and fixed in 4% paraformaldehyde.  After overnight dehydration 
through several steps of ethanol, tissues were then embedded into paraffin 
wax blocks.  Afterwards, embedded-tissues were cut into 4-µm-thick sections 
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placed on SuperFrost slides (Thermo Scientific).  Slides were then stained 
with: H&E (Merck), Periodic Acid Schiff (PAS) Stain Kit (Mucin Stain) (Abcam, 
ab150690) and Picro Sirius Red Stain Kit (Connective Tissue Stain) (Abcam, 
ab150681), according to the protocols provided by manufacturer. 
 
Immunofluorescence (IF) and immunohistochemistry (IHC).  4mm 
paraffin sections were obtained as described above.  Subsequently,   
For immunostainings the following antibody was used: RFP (ab62341, 
Abcam). For nuclei staining DAPI (Cell signaling) was used.  FASN (CS 
#3180), GCS  (bs-0701R) and CRLS1 (ab105782).  Mitochondrial staining 
primary hepatocytes (perfused as described above), from the different mouse 
genotypes were placed on glass coverslips (thickness number 1,5 from VWR) 
in 12-well culture plate.  After cells were attached and equally confluent, 
coverslips were used for immunocytostaining.  Coverslips were placed in a 
homemade box-holder to keep humidity.  After a quick washing step using 
pre-warmed PBS, cells were incubated for 45 min with MitoTracker red 
CMXRos (CS #9082) diluted in pre-warmed media and placed in 37°C.  
Subsequently, cells were washed, fixed, permeabilized and were immediately 
used for staining with Mitofusin-2 (CS #9482S).  Coverslips were mounted on 
a glass slide and sealed using a nail polish.  Slides were then visualized 
using a scanning confocal “LSM800 Inverted“ with AirScan.  
 
Frozen Sections.  Mouse livers were dissected into the different lobes and 
immediately immersed in OCT compound (Tissue Tek; Fisher Scientific; 
Hanover Park, IL) and frozen in 2-methyl butane precooled in liquid nitrogen.  
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Afterwards, tissues were cut into 10-µm-thick sections using a cryostat 
microtome, placed on glass slides on SuperFrost slides (Thermo Scientific), 
air dried, and stored at -80C.  Subsequently, slides were warmed at RT and 
stained with ORO (Sigma) according to standard protocol, and quantified as 
described (Mehlem, Hagberg et al. 2013).  Detection of glycosylceramide was 
performed as described (Sakai, Akiyama et al. 2007).  Briefly, liver frozen 
sections from 20 week-old L-dKO, L-TriKO and control mice were warmed at 
RT and washed twice with PBS, subsequently incubated for 1 hr with 5% 
goat serum for blocking.  Anti-GlcCer antibody (GlycoBiotechTM) was diluted 
with PBS/1% BSA and left for overnight at 4°C.  The same buffer was used to 
dilute an Alexa Fluor® 488 conjugate secondary antibody, followed by 2 
hours incubation at RT.  Stained sections were mounted with Vectashield H- 
1000 (Vector Laboratories, Burlingame, CA).  Images were taken using a 
wide-filed DeltaVision microscope (Olympus IX71) and were de-convoluted. 
 
Blood Analysis.  Plasma free fatty acids was determined using a 
commercial kit (HR Series NEFA-HR(2) and Cayman).  Plasma triglycerides 
(TG), LDL, HDL, and liver damage enzymes ALT, AST, LDH were measured 
using a biochemical analyzer (Cobas c 111 analyzer, Roche). 
 
Hepatic TG Measurement.  Hepatic triglycerides extraction was performed 
as described (Hagiwara, Cornu et al. 2012).  Briefly, ~ 50 mg of mouse liver 
tissue was homogenized in a cold room, for 30 sec (x4, with a 3 min break on 
ice in between, to prevent heating) bead beating in lysing matrix D tubes (Q-
Biogene) containing 1 mL chloroform:methanol (2:1).  Tissue lysate was 
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transferred into a glass tube and 1 mL of distilled water was added.  
Subsequently, tubes were vigorously vortexed for 2 min and centrifuged at 
800 × g for 10 min at 4 °C.  Then, the upper aqueous phase was discarded 
and the lower solvent phase was dried under nitrogen gas at 50 °C, followed 
by re-suspension with 1 mL of chloroform.  Triglycerides were then separated 
by Solid Phase Extraction (SPE) column (Interchim) and dissolved in 
chloroform/Triton X-100 (1%).  Triglyceride levels determined using a 
commercial kit according to manufacturer instructions (TG PAP 150; 
Biomérieux). 
 
Proteome and Phosphoproteome.  For time-course proteome analysis 4, 8 
and 12 week-old L-dKO and control mice were euthanized and livers 
dissected (n=6/group).  For analysis of liver tumors, livers from 20 week-old 
L-dKO mice (n=4) were dissected and separated into individual lobes and 
tumors (3 tumors per mouse) were micro-dissected, and 20 week-old control 
mice were used (n=6).  Tissues were immediately snap-frozen in liquid 
nitrogen.  We performed a ‘cryogenic grinding’, in which a frozen liver biopsy 
was crushed into a fine powder, using an in-house-constructed metal mortar, 
pre-cooled on dry ice.  Subsequently, crushed liver tissues were 
homogenized using a Heidolph homogenizer (RZR 2052 Control) at 300 rpm 
for 2 min.  The lysates were transferred into a cooled 1.5-mL tube containing 
150-400 µL lysis buffer (composed of: 50 mM Tris·HCl (pH 8.0), 8 M urea, 
150 mM NaCl, 1 mM PMSF, Complete Mini Protease Inhibitors (Roche), 100 
mM sodium pyrophosphate/β-glycerophosphate/NaF/NaN3/ para-
Nitrophenylphosphate).  The lysates were vortexed vigorously for 5 min, then 
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sonication in a VWR Ultrasonic cleaner bath (USC300T) for 1 min.  This was 
repeated three times with 2 min rest in between.  Samples were then 
centrifuged at 2500 × g for 10 min at 15°C to remove cell debris.  The protein 
concentration in the supernatants was determined by the Bradford assay.  
Proteins of the supernatants were reduced with 2.5 mM DTT for 1 h at 37°C, 
and alkylated with 50 mM iodoacetamide for 30 min at room temperature in 
the dark.  The urea concentration was reduced to 4 M with 25 mM Tris_HCl, 
pH 8.0.  Protein digestion was performed with two rounds of endoproteinase 
LysC (1:100w/w, Wako) at 37 °C for 2 h.  The urea concentration of the LysC 
digest was reduced to approximately 1.2 M with 100 mM Tris-HCl, pH 8.0.  
Subsequently, trypsin digestion (1:100 w/w) was done for 2 hr at 37°C, 
followed by a second round of trypsin digestion (1:100 w/w) overnight at 37°C.  
Digestion was stopped by adding TFA to 0.4% (vol/vol) final concentration 
that lowered the pH of the solution to below pH 2.0.  Afterwards, the digest 
was centrifuged at 12,000 rpm for 10 min at RT and the pellet was discarded.  
For strong cation exchange chromatography (SCX), the peptides were 
desalted on a C18 reverse-phase SepPak cartridge (Waters).  The peptide 
load was kept to about 5% (w/w) of the weight of the column packing.  The 
cartridges were primed with 5 ml 100% acetonitrile, followed by 5 ml 50% 
AcCN containing 0.5% AcOH and equilibrated with 10 ml 0.1% TFA.  Sample 
was then loaded in 0.4% TFA and the cartridge was washed with 20 ml of 
0.1% TFA.  Finally, TFA was removed with 1 ml of 0.5% AcOH and the 
peptides were eluted with 4 ml of 80% AcCN/0.5% AcOH. The peptide 
peptide concentration was estimated as described (Wisniewski, Zougman et 
al. 2009) and dried in a SpeedVac. 
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SCX (Strong Cation Exchange) Chromatography.  SCX fractionation was 
modified from (Dephoure and Gygi 2011).  Storage buffer was removed from 
a HiTrap SP cartridge (GE Healthcare) and washed twice with 1 mL of SCX 
buffer A {5 mM KH2PO4 (pH 2.65), 30% AcCN}.  Then, the cartridge was 
equilibrated twice with 1 mL of SCX buffer B {5 mM KH2PO4 (pH 2.65), 30% 
AcCN containing 500 mM KCl}, followed by re-eqilibration with 2 mL of SCX 
buffer A.  The dried peptides were resuspended in 2 mL of SCX buffer A, 
centrifuged at 12,000 rpm for 2 min.  The pellet was discarded and peptides 
were loaded with a syringe onto the HiTrap SP cartridge.  The flow-through 
was collected.  The bound peptides were then desorbed in a stepwise 
manner: with 1 mL of SCX buffer A containing 50 mM, 100 mM, 150 mM, 250 
mM, 350 mM, and 500 mM KCl.  Each fraction was collected individually and 
the peptide concentration was estimated at 280 nm.  The fractions were dried 
in a SpeedVac and peptides were then desalted on SepPak cartridges (the 
size of the cartridge was adjusted to the peptide load) as described above.  
The peptide concentration was measured at 280 nm.  20% of each fraction 
was removed for subsequent proteome analysis by LC/MS/MS (see below). 
 
Phosphopeptide Enrichment.  Desalted peptides were dissolved in TiO2-
binding buffer to obtain a peptide concentration of ~ 1ug/uL (Kettenbach and 
Gerber 2011).  TiO2 beads (GL Sciences Inc.) equilibrated in binding buffer 
were then added to the peptide solution.  Adsorption of the peptides to the 
TiO2 beads was done at RT for 1 hr with vigorous shaking.  The beads were 
pelleted at 3000 rpm for 2 min and washed three times with 50%AcCN/0.1% 
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TFA.  Bound peptides (enriched for phosphopeptides) were eluted with 50 
mM K2HPO4, pH 10.  The eluted peptides were immediately acidified with 
50%AcCN/ 5% formic acid.  The enriched phosphopeptide pool was desalted 
on Stage Tips (Thermo Scientific, Reinach, Switzerland), and dried in a 
SpeedVac. 
 
LC/MS/MS Analysis.  The dried phosphopeptides were dissolved in 20 µL of 
0.1% AcOH, 0.005% TFA.  Peptides from the proteomes and 
phosphoproteomes were analyzed by capillary LC/MS/MS using a 
homemade separating column (0.075 mm × 18 cm) packed with Reprosil C18 
reverse-phase material (2.4 µm particle size, Dr. Maisch, Ammerbuch-
Entringen, Germany).  The column was connected on line to an Orbitrap FT 
hybrid instrument (Thermo Scientific, Reinach, Switzerland).  The solvents 
used for peptide separation were 0.1% acetic acid in water/0.005% TFA 
(solvent A) and 0.1% acetic acid/0.005% TFA and 80% acetonitrile in water 
(solvent B).  2 µl of peptide digest were injected with a Proxeon Easy-LC 
capillary pump (Thermo Scientific) set to 0.3 µl/min.  A linear gradient from 0 
to 40% solvent B in solvent A in 190 min was delivered with the nano pump at 
a flow rate of 300 nl/min for the proteome, while a shorter linear gradient of 
95 min under identical conditions for the phosphoproteome was used.  At the 
end of the linear gradient, the percentage of solvent B was increased to 75% 
in ten minutes.  The eluting peptides were ionized at 2.5 kV.  The mass 
spectrometer was operated in data-dependent mode.  The precursor scan 
was done in the Orbitrap set to a 60,000 resolution, while the fragment ions 
were mass analyzed in the LTQ instrument.  A top ten method for the 
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phosphoproteome, and a top twenty method for the proteome were run so 
that the ten or twenty most intense precursors were selected for 
fragmentation. The MS/MS spectra were then searched against a mouse 
databank extracted from the SwissProt databank. 
 
Protein Identification and Data Processing.  The LC/MS/MS data were 
searched with Proteome Discoverer 1.4 (Thermo Scientific) using Mascot and 
Sequest HT search engines set to 10 ppm precursor ion tolerance, while the 
fragment ions were set to 0.6 Da tolerance.  The following modifications were 
used during the search: carbamidomethyl-cysteine was set as a fixed 
modification, protein N-terminal acetylation, oxidized methionine, and 
phosphorylation for serine, threonine, and tyrosine were set to variable 
modifications.  The peptide search matches were set to ‘medium confidence’, 
which corresponds to 5% false discovery rate.  For the searches, the Swiss-
Prot KB database set to M. musculus was used for Mascot, while for Sequest 
HT, a local databank was constructed by extracting all M. musculus entries 
from UniProtKB.  Two missed cleavages were allowed during the searches.  
The peptide false-discovery rate was set to 2%. 
 
Label-free quantification.  The RAW files from the LC/MS/MS were 
imported into the Progenesis software (Non-linear Dynamics, Waters) and the 
matched SCX fractions were aligned.  Alignment was only accepted when the 
histogram of the corresponding feature areas was above 80%.  After 
alignment, the search results of Proteome Discoverer were imported into 
Progenesis for matching the identified peptides with the aligned features.  
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The intensities of all identified features were exported via Excel into a 
FileMaker database.  Class I (≥75% localization probability) was kept for 
further analysis.  
 
Statistical Analysis 
Proteome: The data was analyzed with the Perseus software, version 1.4.0.2.  
For the volcano plots, an ANOVA two-sample t test was performed, adjusting 
S0 to 0.5, number of randomizations to 250, and FDR to 5%.  For the heat 
maps, only proteins that showed at least at one time point a significant 
deregulation were included.  Z-scoring was performed with grouping within 
same time points.   Finally, for unsupervised hierarchical clustering, the 
distance was set to Euclidian, the linkage to average, and the maximal 
numbers of clusters to 300 (Tyanova, Temu et al. 2016). 
Lipidome: The data was analyzed with the Perseus software, version 1.4.0.2.  
For the volcano plots, an ANOVA two-sample t test was performed, adjusting 
S0 to 0.1, number of randomizations to 250, and FDR to 5%.  For the heat 
maps, only proteins that showed at least at one time point a significant 
deregulation were included.  Z-scoring was performed with grouping within 
same time points.   Finally, for unsupervised hierarchical clustering, the 
distance was set to Euclidian, the linkage to average, and the maximal 
numbers of clusters to 300 (Tyanova, Temu et al. 2016). 
 
Lipid Extraction Protocols.  Lipid extraction was performed using a 
modified MTBE protocol (Matyash, Liebisch et al. 2008).  Briefly, for time-
course lipidome analysis fresh liver samples from 4, 8 12 and 20 (cancer 
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tumors were obtained) week-old L-dKO and control mice (n=6/time point) 
were used.  For assessment of mTORC2-regulated lipids, 20 week-old L-
TriKO, L-dKO and control mice were used (n=4/group).  For assessment of 
myriocin lipidome ~20 week-old L-dKO (n=5 myriocin, n=6 vehicle) and 
control (n=5 myriocin, n=4 vehicle) mice were used. As described above, in 
all cases, tissues were immediately snap-frozen in liquid nitrogen.  
Subsequently, tissues were pulverized into a fine powder in an in-house-
constructed metal mortar, pre-cooled on dry ice (‘cryogenic grinding’).  Of that, 
30-35 mg ground liver tissue was resuspended in 100 ml H2O and transferred 
into a 2 ml Eppendorf tube.  Then, 360 ul methanol was added and vortexed.  
A mixture of lipid standards (Table S4) plus 50 ml 1.4 mm Zirconium glass 
beads (Bertin Technologies, France) were added and the pulverized tissue 
was homogenized using a Cryolysis System (Bertin Technologies, France) 
(program: 6200-3x45-045) cooled to 4°C.  MTBE (1.2 ml) was then added 
and the sample was incubated for one hour at room temperature with a 
shaking (750 rpm).  Phase separation was induced by adding 200 ml H2O. 
After 10 minutes incubation at RT, sample was centrifuged at 1000xg for 10 
minutes (RT).  The upper (organic) phase was transferred in a 13 mm screw 
cap glass tube and the lower phase was extracted with 400 ml artificial upper 
phase (MTBE/methanol/water (10:3:1.5, v/v)).  The two upper phases were 
combined and the total lipid extract was divided in 3 equal aliquots (one for 
phospholipids (TL), one for sterols (S) in 2 ml amber vials and one for 
sphingolipid (SL) detection in a 13 mm glass tube) and dried in a Centrivap at 
50°C or under a nitrogen flow.  The TL and S aliquots were ready to be 
analyzed by mass spectrometry and were kept at –80°C.  The SL aliquot was 
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deacylated to eliminate phospholipids by treatment (Clarke method, as 
described (Clarke and Dawson 1981) and (Cheng, Park et al. 2001)) with 0.5 
ml monomethylamine reagent, which was added to the dried lipid, followed by 
sonication (5 min), mixing, incubation for one hour at 53°C and drying, as 
above.  The monomethylamine treated lipids were desalted by n-butanol 
extraction. 300 ml H2O saturated n-butanol was added to the dried lipids. The 
sample was vortexed, sonicated for 5 minutes and 150 ml MS grade water 
was added. The mixture was vortexed thoroughly and centrifuged at 3200xg 
for 10 minutes. The upper phase was transferred in a 2 ml amber vial. The 
lower phase was extracted twice more with 300 ml H2O saturated n-butanol 
and the upper phases were combined and dried (as above). 
 
Phospholipid and Sphingolipid Detection on a Triple Quadrupole LC-MS, 
TSQ Vantage (ThermoFischer Scientific).  LC-MS grade solvents were 
used and the samples were pipetted in a 96 well plate (final volume = 100 ml).  
Positive mode solvent: Chloroform/Methanol/Water (2:7:1, v/v) + 5mM 
Ammonium Acetate.  Negative mode solvent: Chloroform/Methanol (1:2, v/v) 
+ 5mM Ammonium Acetate.  The TL and SL aliquots were resuspended in 
250 ml Chloroform/methanol (1:1 v/v, LC-MS) and sonicated for 5 minutes.  
The TL were diluted 1:10 in negative and positive mode solvents and the SL 
were diluted 1:20 in positive mode solvent and infused onto the mass 
spectrometer using a Nanomate (Advion).  The detection conditions for each 
lipid class are listed in Table S5.  Ceramide species were also quantified with 
a loss of water in the first quadrupole.  Each biological replicate was read in 2 
technical replicates (TR).  Each TR measured 3 times the series of transitions. 
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The phosphate content was also quantified and normalized for each sample. 
Tandem mass spectrometry for the identification and quantification of 
phospho- and sphingolipid molecular species was performed using multiple 
reaction monitoring (MRM) with a TSQ Vantage Triple Stage Quadrupole 
Mass Spectrometer (Thermo Fisher Scientific) equipped with a robotic 
nanoflow ion source, Nanomate HD (Advion Biosciences, Ithaca, NY). Each 
individual ion dissociation pathway was optimized with regard to collision 
energy.  Lipid concentrations were calculated relative to the relevant internal 
standards and then normalized to the total phosphate content of each total 
lipid extract (Ding, Loizides-Mangold et al. 2013). 
 
Determination of Total Phosphorus. The dried total lipid extract was 
resuspended in 250 ml chloroform/methanol (1:1) and 50 ml were placed into 
a 13 mm disposable pyrex tube. The solvent was completely evaporated and 
0, 2, 5, 10, 20 ml of a 3 mM KH2PO4 standard solution were placed into 
separate pyrex tubes. To each tube 20 ml of water and 140 ml of 70% 
perchloric acid were added. Samples were heated at 180C for 1 hour in a 
hood. Tubes were then removed from the block and kept at RT for 5 min. 
Then 800 ml of freshly prepared H2O / 1.25% NH4- Molybdate (100 mg / 8 ml 
H2O) / 10% ascorbic acid (100 mg / 6 ml H2O) in the ratio of 5:2:1 were 
added. Tubes were heated at 100C for 5 min with a marble on each tube to 
prevent evaporation. Tubes were cooled at RT for 5 min. 100 ml of each 
sample was then transferred into a 96-well microplate and the absorbance at 
820 nm was measured. 
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Chemicals for Lipidome Analysis.  Methylmalonic acid (MMA), hydrogen 
chloride (3 M in 1-butanol) and LC MS grade ammonium formate were 
purchased from Sigma-Aldrich. Phosphoric acid (85 wt % solution in water) 
was from Acros Organics (Thermo Scientific).  MTBE was from Fluka (Buchs, 
Switzerland). Methylamine (33% in absolute ethanol) was from Sigma-Aldrich. 
HPLC grade chloroform was purchased from Acros Organics. LC-MS grade 
methanol and LC-MS grade ammonium acetate were from Fluka. LC- MS 
grade water was purchased from Biosolve (Valkenswaard, Netherlands). 
 
Metabolite Extraction Protocol.  Pulverized liver tissue were obtained as 
described above (30-35mg) and re-suspended in 200	  µl extraction solvent 
(ethanol/water/diethylether/pyridine/ammonium hydroxide 4.2N 
(15:15:5:1:0.018)).  To that, a mixture of lipid standards (Table S6) and 50 ml 
1.4 mm Zirconium glass beads (Bertin Technologies, France) were added.  
The pulverized tissue was broken in a Cryolysis System (Bertin Technologies, 
France) (program: 6200-3x45-045) cooled at 4°C.  The sample was 
incubated for 20 minutes on ice, centrifuged at 21000xg for 2 min and the 
supernatant was transferred to an Eppendorf tube.  The pellet was extracted 
a second time with 200	  µl of extraction solvent, and the combined 
supernatants were centrifuged at 21000xg for 5 min to remove remaining cell 
debris and split into two equal aliquots in 300 µl glass inserts. The metabolite 
extract was dried in a Centrivap at 50°C for 30 min and then 60°C for 2 hrs. 
 
Derivatization of Amino Groups.  Was performed as described (Boughton, 
Callahan et al. 2011) with modifications.  Dried lipid extract was re-
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suspended in 10 µl 0.1% formic acid, 70 µl borate buffer (200mM boric acid 
pH 8.8 (with NaOH), 10mM TCEP, 1mM ascorbic acid, 35.7 µM 13C15N –
Valine (internal standard)). The mixture was sonicated for 5 minutes and 20 
µl of 10mM AQC (2.85mg/ml in acetonitrile) was added. The sample was 
incubated for 15 min at 55°C with shaking (750 rpm) followed by overnight 
incubation at 24°C. 
 
LC-MS.  After incubation the sample was centrifuged as above and loaded 
onto a NUCLEOSHELL RP 18 (Particle size: 2.7 µm , length: 100 mm, 
Diameter: 2 mm) and the following gradient was applied:  solvent A : milliQ 
water + 0.1% formic acid, solvent B: isopropanol + 0.1 % formic acid, at a 
flow of 300 ml/min.   
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Supplemental Tables 
 
Table S1 - Supplementary table of RNA sequencing data of lipid related 
genes that are up-or down-regulated in L-dKO/ control mice. Available 
as a separate file. 
 
Table S2 - Supplementary table for enrichment heat map L-dKO/ control 
ad-libitum fed mice (increased). Available as a separate file. 
 
Table S3 - Supplementary table for enrichment heat map L-dKO/control 
ad-libitum fed mice (decreased). Available as a separate file. 
 
Table S4 (related to lipidome analysis): Mammalian standard mix for one 
sample 
 
Standard  nmole Provider Product 
Nr 
DLPC Phosphatidylcholine (PC)12:0-
12:0 
0.4 Avanti 850335 
PE31:1 Phosphatidylethanolamine 
(PE)17:0-14:1 
1 Avanti LM-1104 
PI31:1 Phosphatidylinositol (PI)17:0-
14:1 
1 Avanti LM-1504 
PS31:1 Phosphatidylserine (PS)17:0-
14:1 
3.3 Avanti LM-1304 
CL56:0 Cardiolipin (CL)14:0-14:0-14:0-
14:0 
0.7 Avanti 710332 
C17Cer Ceramide (Cer)d18:1-17:0 2.5 Avanti 860517 
C8GC Glucosylceramide 
(GlcCer)d18:1-8:0 
0.5 Avanti 860540 
C12SM Sphingomyelin (SM) d18:1-
12:0 
0.1 Avanti 860583 
Ergosterol 8 Fluka 45480 
 
Table S5 (related to lipidome analysis): Detection of Lipids by MS/MS 
 
Lipid class standard Polarity Mode m/z ion 
CE 
Phosphatidylcholine 
[M+H]+ PC31:1 + 
Product 
ion 184.07 
30 
Phosphatidylethanol
amine [M+H]+ PE31:1 + 
Neutral 
ion loss 141.02 
20 
Phosphatidylinositol 
[M-H]- PI31:1 - 
Product 
ion 241.01 
44 
Phosphatidylserine 
[M-H]- PS31:1 - 
Neutral 
ion loss 87.03 
23 
Cardiolipin [M-2H]2- CL56:0 - Product ion 
acyl 
chain 
32 
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Ceramide [M+H]+ C17Cer + Product ion 264.30 
25 
Dihydroceramide 
[M+H]+ C17Cer + 
Product 
ion 266.40 
25 
Hexacylceramide 
[M+H]+ C8GC + 
Product 
ion 264.30 
30 
Hexacyldihydrocera
mide [M+H]+ C8GC + 
Product 
ion 266.40 
30 
Sphingomyelin 
[M+H]+ C12SM + 
Product 
ion 184.07 
26 
 
Table S6 (related to metabolome analysis): Standard mice for one 
sample 
 
Standard nmole Provider Product 
Nr 
C17So D-erythro-
sphingosine (C17 base) 
0.04 Avanti 860640 
C17Sa D-erythro-
sphinganine (C17 base) 
0.04 Avanti 
860654 
C17So-1P D-erythro-
sphingosine-1-phosphate 
(C17 base) 
1 Avanti 
860641 
C17Sa-1P D-erythro-
sphinganine-1-phosphate 
(C17 base) 
1 Avanti 
860655 
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Table S7. Primer sequences used for qRT-PCR  
Gene name  Forward (5’- 3’)  Reverse (5’ - 3’)  
acc1 AAGGCTATGTGAAGGATG  CTGTCTGAAGAGGTTAGG  
fasn GCTGCGGAAACTTCAGGAAAT  AGAGACGTGTCACTCCTGGACTT  
scd1 GTCAGGAGGGCAGGTTTC  GAGCGTGGACTTCGGTTC  
acox CTTCAGGCCCAAGTGAGTCA  GCGAACAAGGTCGACAGAAGT  
mcad GATGCCATCACCCTCGTGTAAC  AAGCCCTTTTCCCCTGAAG  
cd36 TGGCCTTACTTGGGATTGG CCAGTGTATATGTAGGCTCATCCA  
mttp TGGTGAAAGGGCTTATTCTGTT  TTGCAGCTGAATATCCTGAGAA  
cyclophilin  TGGAAGAGCACCAAGACAGACA  TGCCGGAGTCGACAATGAT  
apob AAACATGCAGAGCTACTTTGGAG  TTTAGGATCACTTCCTGGTCAAA  
RFP  GCGGCCACTACACCTGCGAC  TCGGCGTGCTCGTACTGCTC  
spk1 GATGCATGAGGTGGTGAATG GCTACACAGGGGTTTCTGGA 
gcs AGCTGGAGAACTGGTCGCTA CACACTGTGCGCCATCAG 
spt(sptlc1) TCGAGTTAAGGCCACAGCTT CATAGAACCCTCGAGGACCA 
smpd acid GGCGAGTACAGCAAGTGTGA CTCCCGTCCAGTACACCATT 
smpd neutral AGTACGAGGACCGGGTTTCT GAGACAACATTGGCAGCAGA 
gpat CAACACCATCCCCGACATC  GTGACCTTCGATTATGCGATCA  
 
  
	   107 
Supplementary findings 
Relevant findings that could not be included in the manuscript are discussed 
below. 
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Inflammation in L-dKO mice. 
As mentioned above, inflammation may further amplify liver damage induced 
by lipids (so called NASH).  L-dKO mice exhibited increased inflammatory 
cytokines, such as tnfa, il6 and probably expansion of resident macrophages 
(kupffer cells), as assessed by the surrogate marker cd68 (Figure 1, below).  
This was confirmed by isolation of inflammatory cells using FACS analysis (8 
week-old L-dKO and littermates control mice).  Specifically, we observed 
elevated levels of Gr1+ inflammatory cells in livers of L-dKO mice.  Gr1+ are 
myeloid infiltrating suppressor cells that promote cancer (Di Mitri, Toso et al. 
2014, Atala 2015).  Immunofluorescence analysis on frozen liver sections 
confirmed the presence of Gr1+ cells.  Gr1+ cells also localized to regions in 
which the sphingolipid GlcCer was present, suggesting a relationship 
between GlcCer accumulation, Gr1+ cells and perhaps cancer.  Furthermore, 
L-dKO exhibited increased spleen mass from 8 weeks of age, suggesting that 
L-dKO mice suffer from systemic inflammatory response (Figure 1, below).  
Indeed, we also identified that elevated Gr1 levels in peripheral blood and 
spleen (not shown).  Together, these data indicates that L-dKO mice display 
hepatic and systemic inflammatory response, whether that is functionally 
related to lipids and/or to tumor development remains to be investigated.  
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Figure 1.  L-dKO mice exhibit hepatic and systemic inflammation.  (A)  Relative 
mRNA in livers from 8 week-old L-dKO and control mice, for the indicated genes.  (B)  
Representative plot of FACS analysis performed on livers from 8 week-old L-dKO 
and control mice.  (C)  Spleen mass from 4, 8, 12 and 200 week-old L-dKO and 
control mice (n=6).  (D)  Representative immunofluorescence images of frozen liver 
sections from tumors of L-dKO mice (control here is non-stained L-dKO). 
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L-dKO mice display enhanced de-novo serine synthesis. 
Serine is required for de novo SL and protein synthesis, as well as a one-
carbon unit source essential for de novo purine synthesis.  In proliferating 
cells, the glycolytic intermediate 3-phosphoglycerate is converted to serine, 
via the de novo serine biosynthesis pathway (SSP) (Locasale 2013, Amelio, 
Cutruzzola et al. 2014).  PHGDH (phosphoglycerate dehydrogenase) 
generates 3-phosphohydroxypurvate, which is subsequently transaminated 
(PSAT1) and dephosphorylated (PSPH) to generate serine.  Cancer cells that 
exhibit genomic amplifications (copy number gain) of PHGDH are dependent 
on serine synthesis (Possemato, Marks et al. 2011, Labuschagne, van den 
Broek et al. 2014, Pacold, Brimacombe et al. 2016).  As depicted in the figure 
below (Figure 2), L-dKO mice exhibit increase de novo serine biosynthetic 
enzymes.  These data suggests that mTOR-driven tumors require serine 
synthesis, probably also for lipid synthesis.  
 
Figure 2.  Increased expression of enzymes in the de novo serine pathway in L-dKO mice.  
Proteins that are up-regulated in livers of L-dKO mice (from 4 to 20 weeks) are depicted in 
red.  Down-regulated enzymes are in blue.  Abbreviation: 6PG, 6-phosphogluconate 
RL5P, Ribulose 5-phosphate; R5P, Ribose 5-phosphate; 6PGD, 6-phosphogluconate 
dehydrogenase; 6PG, 6-phosphogluconolactonase   
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Trends
The clinical beneﬁt of targeted cancer
drugs is limited owing to intrinsic or
adaptive resistance. Mechanisms of
resistance can be cancer cell-autono-
mous or non cell-autonomous.
Drugs can alter the tumor microenvir-
onment, resulting in dynamic rewiring
of signaling circuits and resistance in
neighboring cancer cells.
mTOR signaling is a major compensa-
tory pathway allowing cancer cells to
escape the effects of targeted drugs.
mTOR inhibitors should be considered
as a co-therapy to prevent resistance
to other targeted cancer drugs.
Phosphoproteomics is a novel
approach for elucidating mechanisms
of resistance to targeted therapies.
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Cancer is a complex disease and a leading cause of death worldwide. Extensive
research over decades has led to the development of therapies that target
cancer-speciﬁc signaling pathways. However, the clinical beneﬁts of such
drugs are at best transient due to tumors displaying intrinsic or adaptive resis-
tance. The underlying compensatory pathways that allow cancer cells to cir-
cumvent a drug blockade are poorly understood. We review here recent studies
suggesting that mammalian TOR (mTOR) signaling is a major compensatory
pathway conferring resistance to many cancer drugs. mTOR-mediated resis-
tance can be cell-autonomous or non-cell-autonomous. These ﬁndings suggest
that mTOR signaling should be monitored routinely in tumors and that an mTOR
inhibitor should be considered as a co-therapy.
Resistance Mechanisms Limit the Success of Cancer Therapeutics
Over recent decades many small molecules have been developed to speciﬁcally target onco-
genic pathways. However, with few exceptions, these drugs as a single agent have not led to a
cure. The limited success of targeted drugs is due to tumors displaying resistance. Two modes
of cancer drug resistance exist, intrinsic and adaptive (also referred to as evasive or acquired).
Intrinsic resistance is non-responsiveness to a therapy, whereas adaptive resistance is deﬁned
as responsiveness followed by relapse. Intrinsic resistance is generally the result of a tumor
widely containing a pre-existing mutation that confers resistance in a cell-autonomous manner.
Adaptive resistance can be similarly inherent to the cancer cell, but with the genetic or epigenetic
change arising upon treatment rather than pre-existing. Importantly, adaptive resistance can
also be non-inherent (i.e., non-cell-autonomous) in which resistance relies on the tumor micro-
environment. This latter mechanism involving the microenvironment can be viewed as a
‘physiological’ stress response in which cancer cells are supported by neighboring cells.
Understanding the factors that confer intrinsic or adaptive resistance is important for patient
stratiﬁcation and the rational design of combination therapies. Recent studies suggest that
sustained mTOR signaling, in cancer cells or cells of the microenvironment, confers resistance to
various primary targeted cancer therapies. Thus, mTOR signaling appears to be a major
compensatory pathway conferring resistance to targeted therapies.
The mTOR Signaling Pathway
Growth and proliferation are highly regulated. The evolutionarily conserved serine/threonine
kinase target of rapamycin (TOR) integrates various stimuli to control the metabolic pathways
that drive cell growth and proliferation (Figure 1). TOR forms two structurally and functionally
distinct multiprotein complexes termed TOR complex 1 (TORC1) and TORC2 (reviewed in [1,2]).
In mammals, mTORC1 contains mTOR, mammalian lethal with sec-13 protein 8 (mLST8), and
regulatory associated protein of mammalian target of rapamycin (RAPTOR). mTORC1 is
activated by growth factors, nutrients, and cellular energy (reviewed in [3,4]), and is acutely688 Trends in Cancer, November 2016, Vol. 2, No. 11 http://dx.doi.org/10.1016/j.trecan.2016.10.006
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Figure 1. mTOR Signaling Network. mTOR signaling promotes cancer cell growth, survival, and proliferation. (A)
Growth factors such as insulin (Ins) stimulate PI3K to convert phosphatidylinositol-4,5-bisphosphate (PIP2) to phospha-
tidylinositol-3,4,5-trisphosphate (PIP3). PIP3 stimulates PDK1 to phosphorylate (P) AKT at T308. AKT phosphorylates TSC2
on multiple sites, thereby inhibiting its GAP activity toward RHEB. GTP-loaded RHEB binds to and activates mammalian
TOR complex 1 (mTORC1). Growth factors also activate mTORC2 in a PI3K- and ribosome-dependent manner. mTORC2
phosphorylates and activates the AGC kinase family members SGK1 and AKT. mTORC2 phosphorylates AKT at Ser473.
mTORC2 is not upstream of mTORC1 because AKT Ser473 phosphorylation is not required for mTORC1 activation. (B)
Amino acids stimulate mTORC1 by promoting the conversion of RAS-related GTP-binding protein (RAG) heterodimers to
the active conformation, in which RAGA or RAGB is loaded with GTP, and RAGC or RAGD is loaded with GDP. Active RAG
heterodimer recruits mTORC1 to the surface of the lysosome where mTORC1 encounters its direct activator RHEB. (C) c-
MYC, whose expression is repressed by FOXO, mediates cancer cell metabolic reprogramming. In an AKT-independent
manner, mTORC2 inhibits class II HDACs, thereby increasing FOXO acetylation (Ac). Ac-FOXO is retained in the cytoplasm,
unable to inhibit c-MYC expression. mTORC2 also inhibits FOXO via AKT. (D) In response to low energy (high AMP/ATP
ratio), AMP-activated protein kinase (AMPK) inhibits mTORC1 activity by phosphorylating RAPTOR at S792 and S722, and
by phosphorylating TSC2. The tumor-suppressor liver kinase B1 (LKB1) activates AMPK/ by phosphorylating T172 in the
activation loop. Blue-colored proteins are tumor-suppressors that inhibit mTOR activity. Phosphorylation depicted in green
is an activation signal and phosphorylation depicted in red is an inhibitory signal. Abbreviations: Ac, acetylation; GH, growth
hormone; NDRG1, N-MYC downstream-regulated gene 1.inhibited by the macrolide rapamycin. Rapamycin (and its analogs known as rapalogs) binds to
the cytoplasmic protein FKBP12 (FK506-binding protein 12), and the FKBP12–rapamycin
complex then binds to the FRB (FK506-binding protein/rapamycin-binding) domain in mTOR
of mTORC1 [5]. Several mTOR inhibitors are approved or in clinical trials for cancer therapy
(reviewed in [5–7]). mTORC2 is not acutely inhibited by rapamycin, presumably because the FRB
domain in mTOR in mTORC2 is masked [8]. Growth factors and cellular energy stimulate
mTORC1 via inhibition of the heterotrimeric protein complex consisting of tuberous sclerosisTrends in Cancer, November 2016, Vol. 2, No. 11 689
complex 1 (TSC1), TSC2, and TRE2–BUB2–CDC16 domain family member 7 (TBC1D7) [9–14],
hereafter referred to as the TSC complex. Insulin (or other growth factors) bind to receptor
tyrosine kinases (RTKs) to activate phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). PI3K
phosphorylates the inositol ring of the membrane phospholipid phosphatidylinositol-4,5-
bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3) [15]. PIP3
recruits phosphoinositide-dependent kinase 1 (PDK1) and AKT to the plasma membrane
[16]. PDK1 phosphorylates Thr308 in the activation loop of AKT and thereby activates AKT
[17]. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) converts PIP3 to
PIP2, counteracting the activity of PI3K. AKT phosphorylates TSC2, thereby inducing lysosomal
release and inhibition of the TSC complex [10,11,18]. The TSC complex is a GTPase-activating
protein (GAP) for the lysosomal GTP-binding protein RAS homolog enriched in brain (RHEB).
GTP-loaded RHEB interacts with the mTOR catalytic domain and activates mTORC1 [19].
mTORC1 promotes anabolic processes such as protein, lipid, and nucleotide biosynthesis, and
inhibits catabolic processes such as autophagy. Notable downstream targets of mTORC1 are
ribosomal protein S6 kinase (S6K), eukaryotic translation initiation factor 4E binding proteins (4E-
BPs), and the autophagy activating Unc-51-like kinase 1 (ULK1) (reviewed in [20–22]) (Figure 1).
mTORC2 contains mTOR, mLST8, mammalian stress-activated mitogen-activated protein
kinase (MAPK)-interacting protein 1 (mSIN1), and rapamycin-insensitive companion of mTOR
(RICTOR). Growth factors activate mTORC2 by promoting association of mTORC2 with
ribosomes in a PI3K-dependent manner [23]. PIP3 interacts with the PH domain of mSIN1
to trigger mTORC2 activation [24]. mTORC2 regulates several cellular processes via activation of
the AGC kinase family members AKT, protein kinase C (PKC), and serum/glucocorticoid-
regulated kinase (SGK) (reviewed in [25,26]). mTORC2 phosphorylates Ser473 in AKT. In a
positive feedback loop, AKT phosphorylates mSIN1-Thr86 in mTORC2 [27]. In a negative
feedback loop, mTORC1 via S6K phosphorylates and inhibits the insulin receptor substrate
1 (IRS-1), thereby dampening PI3K signaling [28–30] (Figure 1). mTORC1 and mTORC2 are
frequently activated in human cancers. Genetically engineered mouse models with ectopic
activation of mTORC1 or mTORC2 develop cancer [31–34]. mTOR, often in the context of
positive and negative feedback loops, is a node for convergence and crosstalk of several
oncogenic pathways (Figures 1,2) [30,35–37].
mTOR Signaling in Cell-Autonomous Resistance
Extracellular signal-regulated kinase (ERK) is a MAPK and the major effector of the GTPase
Kirsten rat sarcoma viral oncogene homolog (KRAS) (Figure 2). Ligand-mediated activation of
RTKs triggers GTP loading of KRAS, which then recruits the kinase BRAF to the plasma
membrane for activation [38]. BRAF phosphorylates and activates the MAPK kinase MEK.
MEK activates ERK that in turn phosphorylates cytoplasmic signaling proteins, including p90
ribosomal S6 kinase (RSK). ERK and RSK phosphorylate and inhibit TSC2, leading to activation
of mTORC1. Furthermore, it has been suggested that RSK phosphorylates several sites in
RAPTOR to enhance mTORC1 activity [39]. Finally, ERK and mTORC1 provide distinct activat-
ing inputs to eukaryotic translation initiation factor 4E (eIF4E), thereby promoting cap-dependent
mRNA translation [40]. Thus, mTOR and ERK signaling are functionally related.
The ERK kinase network is constitutively active in about 40% of human melanomas [41] (Figure 2).
Loss of the tumor-suppressor PTEN, which leads to activation of mTOR signaling, confers poor
response to BRAF inhibitors in melanoma patients [42–44]. Indeed, these patients deﬁne a
distinct subset of melanoma that is resistant to BRAF inhibitors. Melanoma cell lines and human
patient samples that exhibit resistance to BRAF, MEK, or ERK inhibitors display enhanced S6-
S235/236 and S240/244 [45,46] or AKT-Ser473 phosphorylation [47–49], readouts of mTORC1
and mTORC2, respectively. Thus, PI3K–mTOR signaling appears to compensate for loss of ERK
signaling and thereby confers resistance to BRAF-MEK-ERK inhibitors. mTOR may compensate
by substituting for ERK signaling in phosphorylating particular substrates [50].690 Trends in Cancer, November 2016, Vol. 2, No. 11
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Figure 2. mTOR Signaling and Resistance to Targeted Drugs. (A) AXL is a RTK that is activated through ligand
(GAS6)-dependent or -independent dimerization. In head and neck, and esophageal squamous cell carcinomas dimeriza-
tion of AXL and EGFR contributes to drug resistance via activation of mTORC1. AXL phosphorylates EGFR at Y1173 that in
turn serves as a docking site for phospholipase Cg (PLCg). PLCg at the plasma membrane cleaves PIP2 to produce the
second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates members of the serine/
threonine protein kinase C (PKC) family. By an unknown mechanism, PKC activates mTORC1, thereby promoting
resistance to several drugs. (B) The mTOR and ERK pathways respond to extracellular and intracellular cues to control
cell survival, proliferation, and metabolism. SOS1 is a guanine nucleotide exchange factor for the GTPase KRAS. GTP-
loaded KRAS recruits BRAF kinase to the plasma membrane for activation. BRAF phosphorylates and activates MEK. MEK
activates ERK that phosphorylates cytoplasmic signaling proteins, including RSK and MNK. ERK and RSK phosphorylate
and inhibit TSC2, thereby activating mTORC1. RSK phosphorylates RAPTOR on several sites to enhance mTORC1 activity.
RSK also phosphorylates ribosomal protein S6 at the Ser235 and Ser236. ERK and mTORC1 provide distinct and
complementary inputs to eIF4E, thereby promoting mRNA translation (not shown). The ERK pathway is activated in
melanoma and pancreatic tumors. In these tumors, targeted inhibition of the ERK pathway promotes both mTORC1 and
mTORC2 activation, and thereby resistance to the ERK pathway inhibitors. (C) The cyclin D–cyclin-dependent kinase (CDK)
4/6–retinoblastoma (RB) pathway regulates cell-cycle progression. Unphosphorylated RB binds to and inhibits E2F
transcription factors. CDK4/6–cyclin D phosphorylates the tumor-suppressor RB that dissociates from E2F, allowing
cell-cycle progression. Resistance to CDK4/6 inhibitors is associated with increased mTORC1 activity in breast and
pancreatic cancers. Although the connection between CDK4/6–cyclin D and mTORC1 signaling is poorly understood,
mTORC1 activation limits the killing effect of cell-cycle inhibitors. (D) Brain tumor cells containing an EGFRvIII ampliﬁcation
exhibit enhanced mTORC2 activity. mTORC2 mediates metabolic reprogramming and resistance to targeted drugs by
increasing expression of c-MYC. Abbreviations: GRB2, growth factor receptor-bound protein 2; RTK, receptor tyrosine
kinase; SOS, son of sevenless homolog 1.PI3K activating mutations are common in various human cancers [51]. In breast cancer cells
containing a PIK3CA mutation, resistance to the PI3K inhibitor BLY719 correlates with S6
hyperphosphorylation, and mTOR inhibition restores sensitivity to BLY719 [52]. Similarly, mTOR
signaling confers resistance to PI3K inhibitors in thyroid tumor cells [53]. Thus, mTOR activation
confers resistance to PI3K inhibitors.Trends in Cancer, November 2016, Vol. 2, No. 11 691
The transcription factor c-MYC promotes tumor progression and metabolic adaptation [54]
(Figure 2). mTORC2-dependent c-MYC overexpression, and thereby enhanced aerobic glycol-
ysis, confers resistance to a PI3K inhibitor in glioblastoma multiforme (GBM) [47,55]. Thus,
mTOR appears to confer resistance to PI3K inhibitors also via upregulation of c-MYC.
The cyclin-dependent kinase (CDK) 4/6–retinoblastoma (RB) pathway regulates cell-cycle
progression [56] and is implicated in various cancers [56–58] (Figure 2). Unphosphorylated
RB binds and represses E2 family (E2F) transcription factors. CDK4/6 in association with cyclin
D1 phosphorylates the tumor-suppressor RB that in turn dissociates from E2F, allowing cell-
cycle progression. Resistance to CDK4/6 inhibitors is associated with increased mTORC1
activity in cell lines [59] as well as in mouse models of breast [60] and pancreatic [61] cancers.
Although the connection between CDK4/6–cyclin D and mTORC1 signaling is poorly under-
stood, these studies indicate that mTORC1 activation limits the killing effect of cell-cycle
inhibitors. Interestingly, phosphorylated RB appears to interact directly with mSIN1 to inhibit
mTORC2 [62], suggesting that mTORC2 activation may occur in response to a CDK4/6 inhibitor
and confer resistance to the drug. Thus, an ATP competitive pan-mTOR inhibitor that targets
both mTORC1 and mTORC2 could be considered as a co-therapy with a CDK4/6 inhibitor.
AXL is a member of the TAM (TYRO, AXL, and MER) family of receptor tyrosine kinases (reviewed
in [63,64]) (Figure 2). AXL is activated in many ways including homodimerization or heterodime-
rization with a non-TAM receptor [65]. AXL activation is associated with acquired resistance to
PI3K, RTK, BRAF, and MEK inhibitors [66]. In head and neck, and esophageal squamous cell
carcinoma cells treated with a PI3K inhibitor, AXL dimerizes with and phosphorylates EGFR.
Phosphorylated EGFR-Y1173 is a docking site for phospholipase Cg (PLCg). PLCg, via the
second messenger diacylglycerol (DAG), activates the serine/threonine protein kinase C (PKC). Via
an unknown mechanism, PKC activates mTORC1 [67], thereby conferring resistance to the PI3K
inhibitor [68] (Figure 2). In cell lines and human lung tumor samples, AXL activation is associated
with resistance to the EGFR inhibitors erlotinib [69] and geﬁtinib [70], respectively. Given the above
study demonstrating that AXL can activate EGFR and ultimately mTORC1 to confer resistance to a
PI3K inhibitor, AXL-mediated resistance to EGFR inhibitors is possibly also via mTORC1.
The above studies indicate that activation of the mTOR pathway can confer resistance to various
targeted therapies. This underscores the complex interplay between mTOR and other major
oncogenic pathways, and how such interplay can be exploited for resistance. These studies also
suggest that patients should be routinely monitored for mTOR activity, and a co-therapy with an
mTOR inhibitor should be considered. Clearly, the clinical application of combination therapies
should be evaluated against the risk of side effects, in particular the combination of mTOR and
MAPK inhibitors [71,72].
What are the genetic alterations leading to activation of mTOR signaling and cell-autonomous
resistance? Cancer cell lines exposed to increasing doses of geﬁtinib exhibit MET (receptor
tyrosine kinase) gene ampliﬁcation, which in turn leads to PI3K–mTOR pathway activation and
geﬁnitib resistance [73]. Although not equivalent to activating a compensatory pathway, muta-
tion of the FRB domain in mTOR in a human thyroid carcinoma conferred resistance to the
allosteric mTOR inhibitor everolimus (rapamycin), possibly accounting for the patients’ relapse
[74]. Although little is known about the mTOR activating mutations that confer cell-autonomous
resistance, these studies suggest that such alterations occur within MTOR or in a gene encoding
an mTOR regulator.
mTOR Signaling in Non-Cell-Autonomous Resistance
mTOR signaling can also confer resistance to targeted drugs in a non-cell-autonomous manner
(Figure 3). In this case, activation of mTOR in cells of the tumor microenvironment confers692 Trends in Cancer, November 2016, Vol. 2, No. 11
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Figure 3. mTOR Confers Resistance in Response to Changes in Cancer Cells or in Stromal Cells (Tumor
Microenvironment). Resistance to a targeted therapy can be inherent to the cancer cell or rely on the tumor micro-
environment. (A,B) Cancer cell-inherent mechanisms of resistance can be genetically or non-genetically determined.
Genetic alterations that activate mTOR to confer resistance may be loss of a tumor-suppressor or acquisition of an
oncogene. Non-genetic responses that confer resistance may be dynamic, compensatory signaling changes induced by
the drug.
A tumor is a mixture of transformed and non-transformed cells supported by an extracellular matrix, which together form the
so-called tumor microenvironment. (C,D) Cells of the tumor microenvironment, in addition to cancer cells, include immune,
vasculature, and lymphatic cells as well as cancer-associated ﬁbroblasts (CAFs). Antitumor drugs affect both cancer cells
and other cells of the microenvironment. In response to a drug the cells of the tumor microenvironment, such as CAFs or
cancer cells that respond to the drug, secrete poorly deﬁned factors referred to as the TIS (therapy-induced secretome). The
TIS can act in a paracrine manner to promote resistance. (E) Immune cells play an important role in tumor eradication. mTOR
in cancer cells promotes the expression of PD-L1 to suppress tumor-invading immune cells. (F) mTOR in senescent cells
regulates the senescence-associated secretory phenotype (SASP). SASP is composed of various cytokines, growth
factors, and proteases that modulate the tumor microenvironment. mTORC1 mediates SASP secretion from senescent
cells that promotes the resistance and proliferation of nearby cancer cells. (G) Cancer cells operate in different metabolic
compartments and secrete metabolites in response to targeted drugs. Nutrients and metabolites in the tumor micro-
environment may activate mTORC1 to confer resistance.resistance on nearby cancer cells. The cells of the microenvironment that confer resistance in a
paracrine manner can be stromal cells or cancer cells. Non-autonomous resistance is a drug-
induced stress response that is context-dependent and may disappear once the drug (stress) is
removed.
Tumors are a heterogeneous population of cells, composed of cancer cells and supporting
stromal cells. The therapy-induced secretome (TIS) is a collection of ill-deﬁned factors that are
secreted in response to therapy. Stromal TIS can induce extensive changes in the tumor niche to
confer drug resistance on nearby cancer cells [75–77]. In this case, the TIS from cancer-
associated ﬁbroblasts (CAFs) promotes RTK phosphorylation and thereby mTOR activation in
neighboring colorectal or pancreatic cancer cells. In melanoma, the cancer cells respond to the
targeted therapy and secrete the TIS component mitogen FOS-related antigen 1 (FRA1). FRA1
activates PI3K–mTOR signaling and promotes resistance in neighboring cancer cells [78].
Finally, mTORC1–4EBP1 signaling controls the TIS in CAFs derived from human pancreaticTrends in Cancer, November 2016, Vol. 2, No. 11 693
Outstanding Questions
What are the cell-autonomous genetic
alterations that lead to the activation of
mTOR in response to a targeted drug,
thereby conferring resistance?
What are the mTOR-dependent non-
cell-autonomous changes that could
be clinically exploited to limit resistance
in cancer cells?
Resistance to a targeted drug is also
determined by the spatial and cellular
complexity of the tumor. What
approaches should be taken to deci-
pher tumor complexity, especially in
human tumors?
How can one monitor mTOR activity
longitudinally in human patients under-
going targeted therapy?
What regimen should be used for an
mTOR inhibitor as a co-therapy?tumors [79]. Thus, mTOR plays a dual role in controlling the tumor microenvironment, in other
words in sending and receiving the TIS signal to promote cancer resistance to targeted drugs.
Therapy also induces a so-called senescence-associated secretory phenotype (SASP) that can
modulate the tumor microenvironment. Therapy may induce cancer cells to secrete SASP
factors that are tumorigenic by blunting the effect of the drug on other (non-senescent) cancer
cells [80,81]. Two recent studies showed that mTORC1 in senescent cancer cells mediates
SASP. Rapamycin selectively abrogates SASP, and thereby improves therapy response in
prostate [82] and liver [83] tumor xenografts. This suggests that mTOR can modulate the cancer
microenvironment by promoting SASP, and thereby confer therapy resistance in a non-cell-
autonomous manner.
Cancer cells present programmed death ligand 1 (PD-L1) to the T cell-borne receptor PD-1. This
results in suppression of the T cell, thereby allowing tumor cells to evade killing by the immune
system. PD-1 or PD-L1 inhibition, so-called immunotherapy, prevents cancer cells from evading
the immune system and is thus an anticancer therapy, particularly effective in the treatment of
melanoma. However, PTEN deﬁcient melanomas in which PI3K–mTOR signaling is hyperactive
are resistant to immunotherapy. In this context, co-treatment with a PI3K inhibitor improves the
efﬁcacy of at least PD-1 inhibition [84]. Furthermore, mTORC1 signaling drives PD-L1 expression
in a rapamycin-sensitive manner in mouse models of non-small cell lung carcinoma [85]. Thus,
PI3K–mTOR signaling in cancer cells mediates immune evasion and thereby tumor resistance to
immunotherapy.
Tumors display complex spatial organization. Cancer cells operate in different metabolic
compartments within a tumor and communicate through released metabolites or nutrients.
Sonveaux et al. [86] showed that cancer cells in hypoxic regions of a tumor perform aerobic
glycolysis and consequently excrete lactate. Neighboring cancer cells in normoxic regions of the
tumor take up the lactate, via monocarboxylate transporter 1 (MCT1), and utilize it for oxidative
respiration. This phenomenon in which tumor cells feed other tumor cells is referred to as
metabolic symbiosis. Anti-angiogenic cancer therapy partly disrupts blood vessels, thereby
creating hypoxic and normoxic compartments in tumors. Recently, three groups demonstrated
that angiogenesis inhibitors induce metabolic symbiosis [87–89]. Importantly, the drug-induced
metabolic symbiosis is mTOR-dependent and confers drug resistance [87,88]. Glutamine-
activated mTORC1 promotes MCT1 expression and, in turn, lactate uptake in normoxic cells
[87,90]. Thus, the normoxic cells utilize lactate as a carbon source, sparing the available glucose
for the hypoxic, glycolytic cells that symbiotically feed the normoxic, oxidative cells. The net effect
is that cancer cells both near and far from blood vessels survive anti-angiogenic therapy.
Rapamycin administration disrupts therapy-induced metabolic symbiosis, leading to tumor
regression [87,88]. Furthermore, mTORC1 confers resistance to the glycolysis inhibitor
2-deoxyglucose (2-DG), in a glutaminolysis-dependent manner [91]. In summary, mTORC1
promotes metabolic symbiosis to confer adaptive resistance to angiogenesis inhibitors in a
non-cell-autonomous manner.
Concluding Remarks
mTOR signaling is emerging as a major compensatory pathway allowing tumors to escape
targeted cancer therapies. mTOR may be a common escape route because it is a central
signaling hub functionally related to other oncogenic pathways. Resistance mechanisms can be
cell-autonomous or non-cell-autonomous. Non-cell-autonomous resistance is generally adap-
tive, reversible, and dependent on the tumor microenvironment. Drugs modify the tumor
microenvironment, not only the targeted cancer cells. In particular, they stimulate stromal cells
and cancer cells to secrete factors that can confer drug resistance to neighboring tumor cells.
Importantly, mTOR can mediate both the secretion of such factors and the response to the694 Trends in Cancer, November 2016, Vol. 2, No. 11
Box 1. The Use of Phosphoproteomics To Study Mechanisms of Resistance to Targeted Cancer
Drugs
Genomic analysis of various human cancers has identiﬁed key driver and resistance-conferring mutations, often affecting
kinases in signaling pathways [92]. Whereas genomic analysis has been very effective, it only indirectly examines
oncogenic signaling pathways. To elucidate signaling changes in response to targeted drugs, phosphorylation cascades
can be monitored directly. Mass spectrometry (MS)-based proteomics, in particular phosphoproteomics, is a powerful
tool to monitor directly the effect of targeted drugs on oncogenic signaling pathways [93]. However, caution should be
taken when performing phosphoproteomics to avoid complications due to rapid dephosphorylation [94]. Phospho-
proteins belonging to the MAPK and mTOR signaling pathways are particularly sensitive to ischemia [95] or hypogly-
cemia. Dynamic signaling cascades are best monitored by analyzing immediately snap-frozen needle biopsies in which
tumor conditions are preserved [96].
The usefulness of phosphoproteomics in elucidating resistance mechanisms is underscored by a recent study by Wei
et al. [97]. Mice transplanted with patient-derived GBM cells were treated with mTOR inhibitors. Cancer cells that
developed resistance were then subjected to genomic and phosphoproteomic analyses. Phosphoproteomics revealed
marked deregulation of mTOR-related signaling pathways in resistant tumors, suggesting a rewiring of protein signaling
networks. However, in-depth genomic analysis did not identify signiﬁcant genetic changes in resistant tumors versus
non-resistant tumors. In another recent study, Dazert et al. [50] performed phosphoproteomics on serial biopsies from a
sorafenib-treated hepatocellular carcinoma (HCC) patient, taken before and during treatment, to identify mechanisms of
resistance to sorafenib. Sorafenib acts by inhibiting RAF (B and C), vascular endothelial growth factor receptor (VEGFR),
and platelet-derived growth factor receptor (PDGFR) [98]. Sorafenib is the only approved targeted drug for HCC, with
median enhanced survival of <3 months [99]. Dazert and colleagues demonstrated that sorafenib was effective in
inhibiting its target in the tumor, based on reduced RSK phosphorylation downstream of BRAF–MEK–ERK signaling.
However, phosphorylation of the putative MAPK target Filamin A S2152 and the mTORC1 target S6-S240 was increased
in the sorafenib-treated tumor, indicating that a compensatory pathway(s) may have been active in the sorafenib-resistant
tumor. Phosphoproteomic analysis of a cohort of patients will provide a more complete picture of the mechanisms of
sorafenib resistance.factors in a recipient cancer cell. The seemingly central role of mTOR in conferring therapy
resistance suggests that effective therapy may require combination of an inhibitor of the primary
tumor driver and an mTOR inhibitor as co-therapy. To prevent resistance to the co-therapy,
intermittent administration should be considered.
Mechanisms of adaptive or intrinsic resistance to targeted drugs are poorly characterized (see
Outstanding Questions). The identities of the compensatory signaling pathways and the func-
tional interconnections that underlie resistance are largely unknown. Whereas genomic analysis
has been very effective in identifying oncogenic pathways, elucidating the dynamic pathways
that confer resistance may require a combination of genomic and phosphoproteomic analyses
(Box 1). In particular, tumor biopsies obtained before and during treatment in a longitudinal study
should be assessed by mass spectrometry to determine drug-related changes in dynamic
phosphorylation cascades. Tumor heterogeneity is a major limitation, especially when human
biopsy specimens are limited. Efforts from computational biologists will be important in resolving
this complexity.
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